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ABSTRACT 
Commercial modified live (MLV) and killed (KV) porcine reproductive and 
respiratory syndrome virus (PRRSV) vaccines induce slow developing effective immunity as 
measured by serum neutralizing (SN) antibody and cell-mediated immunity. The objective of 
the studies was to develop more effective vaccines or vaccination strategies based on 
commercial vaccines. Three separate studies were conducted to investigate the efficacy of 
vaccination protocols including vaccination with MLV and KV, either alone or in 
combination, KV with interleukin (IL)-12 added, and KV used as a booster vaccine in a 
PRRSV positive herd. The protection induced was evaluated by experimentally challenging 
pigs with PRRSV. 
It was found that the MLV followed by KV induced significantly higher SN antibody 
levels compared to either vaccine alone. This vaccination protocol significantly reduced 
serum viral RNA, severity of lung lesions, and clinical disease. In contrast, the addition of 
IL-12 did little to enhance the efficacy of the KV although clinical respiratory disease 
consistent with PRRSV was significantly reduced. However, no reduction of viral RNA in 
serum or reduced persistence of virus in tonsils or lung lavage samples was observed. The 
KV administration to gestational sows significantly increased SN antibodies in serum and 
colostrum at farrowing and at weaning compared to non-vaccinated sows. Furthermore, pigs 
farrowed from the vaccinated sows had significantly higher levels of maternally derived 
antibodies (MDA) as measured by both SN and ELISA assays compared to pigs farrowed 
from the non-vaccinated sows. Pigs farrowed from vaccinated sows and challenged at 10 
days of age displayed the mildest clinical disease and had lower levels of serum viral RNA 
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than pigs from non-vaccinated sows. Incomplete reduction of serum viral RNA and lung 
lesion suggests incomplete protection provided by MDA. 
The present studies provide useful information to the swine industry as a combination 
vaccination protocol, MLV followed by KV, could be used for reducing PRRSV clinical 
disease and viremia. In addition, KV can be used as a booster vaccine to enhance the existing 
immunity of sows in a PRRSV positive herd, resulting in enhanced MDA levels in piglets. 
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CHAPTER 1. GENERAL INTRODUCTION 
STATEMENT OF PROBLEM 
Porcine reproductive and respiratory syndrome virus (PRRSV) causes a disease in 
swine characterized by disorders of the reproductive and respiratory systems (Wensvoort et 
al., 1991; Collins et al., 1992). Since its first emergence in the late 1980's, PRRSV has 
continued to have a significant economic impact to the swine industry worldwide. Economic 
losses following PRRSV outbreaks have been estimated to range from $236 to $502 per sow 
depending on the type of operating system (Poison et al., 1992). To reduce the economic 
effects of PRRSV, numerous management protocols including total depopulation and 
repopulation with naive pigs, partial depopulation, test and removal, isowean, whole herd 
vaccination, and temporary herd closure have been used (Andreasen et al., 1998; Dee and 
Molitor, 1998; Gramer et al., 1999; Philips et al., 2000; Torremorell et al., 2000). However, 
the success of these various programs has varied. In addition, although many herds have 
successfully eliminated PRRSV, re-occurrence of PRRSV is a common event issue. At 
present, a definitive solution for preventing and controlling PRRSV has not been discovered. 
In many production systems, PRRSV control is based on maintaining sufficient herd 
immunity to avoid clinical disease and reduce virus shedding in the sow herd, which enables 
the production of PRRSV negative weaned pigs. Vaccination is frequently used to induce 
and/or maintain herd immunity. However, at present, there are no PRRSV vaccines that are 
sufficiently safe and/or protective for general use in all production situations and vaccine 
failure as demonstrated by the occurrence of clinical outbreaks in vaccinated herds are 
frequently observed. Furthermore, several investigators have demonstrated that the current, 
commercially available vaccines are not effective in the induction of effective immune 
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responses. Both modified live (MLV) and killed (KV) PRRSV vaccines appear to be unable 
to stimulate sufficiently strong cellular immune responses or induce significant serum 
neutralizing (SN) antibody titers following administration (Osorio et al., 1998; Meier et al., 
2000). Furthermore, pigs vaccinated with PRRSV MLV may spread the vaccine virus to non-
vaccinated pigs, which is a significant limitation of MLV use in both PRRSV naïve and 
positive herds (Botner et al., 1997). The efficacy of PRRSV KV is also highly questioned. 
Vaccination in naïve pigs with KV does not induced antibody response as measured by 
ELISA or SN assays, but a slight cell-mediated immune (CMI) response is observed 
(Bassaganya-Riera et al, 2004). In addition to the incomplete efficacy of PRRSV vaccines, it 
appears that new commercial PRRSV vaccines will be slow reach the market any time in the 
near future because of intellectual property issues. Therefore, improved vaccine strategies 
based on modifying currently existing vaccines or improved vaccination strategies are 
urgently needed to provide solutions readily available to producers. 
GENERAL OBJECTIVES AND RESEARCH PLAN 
In the studies reported here, we investigated modifications of KV regimens. Although 
vaccination of naïve pigs with KV does not appear to induce a strong cellular immune 
response or detectable antibody response, we proposed and then studied the use of alternative 
adjuvants for enhancing KV efficacy. In addition, several reports of enhanced immune 
responses by KV, as demonstrated by increased SN antibody levels, have been observed in 
pigs that had been previously infected with field viruses or vaccinated with MLV compared 
to MLV or KV alone (Baker et al., 1999; Nilubol et al., 2004; Bassaganya-Riera et al., 2004). 
These reports suggest that the use of combined MLV and KV vaccination protocols should 
be further investigated as potentially more effective PRRSV vaccination strategies. Based on 
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these findings, studies were conducted to explore the use of combined MLV and KV PRRSV 
vaccination. The overall objective of the studied reported here was to determine if 
modification of the current KV or developing alternative vaccination strategies could 
enhance the immune status of swine herds using commercially available PRRSV MLV and 
KV, either alone or in combination. The immune responses elicited by vaccination were 
characterized and their ability to protect against experimental challenge was evaluated in 
three separate studies. 
The first study investigated if the addition of IL-12 to KV would enhance the overall 
immune response and specially, CMI response, induced by KV. The use of IL-12 as an 
adjuvant was based on its role in the differentiation of T helper (Th) 0 cells to Th 1 cells 
following exposure to antigen. A previous study demonstrated that the addition of IL-12 as 
an adjuvant to a pseudorabies vaccine enhanced vaccine efficacy (Zuckermann et al., 1998). 
In this study, we also investigated whether MLV vaccination followed by KV would result in 
a stronger immune response compared to vaccination with either vaccine alone. 
A second study was conducted to characterize both the humoral and CMI responses 
induced by vaccination with MLV and KV PRRSV vaccines, either alone or in combination. 
In this study, antibody responses were measured by ELISA and SN assays and the CMI 
response was measured using lymphocyte proliferation assays. In addition, protective 
immunity induced by the vaccines was evaluated by experimental challenge by high or low 
virulent PRRSV isolates. 
The third study was conducted in a PRRSV positive herd with a history of MLV use 
and periodic outbreaks of field viruses. This study was conducted to investigate the ability of 
PRRSV KV to boost the existing immunity of previously PRRSV-exposed sows during 
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gestation thus increasing the magnitude and duration of maternally derived antibody (MDA) 
in their offspring. It was hypothesized that the increased levels of MDA in piglets would 
enhance protection against experimental PRRSV infection. 
The information gained from the reported studies should provide important 
information to aid in developing more effective vaccination strategies that would counteract 
the devastating effects of PRRSV based on currently available, commercial vaccines. 
DISSERTATION ORGANIZATION 
This dissertation is written in the alternative format and is organized into five 
chapters. The first chapter contains statement of problem, general objectives and research 
plan, dissertation organization and literature review. Chapters two through four are the 
author's research, in manuscript format prepared for publication. The fifth chapter includes 
general conclusions summarizing the results of these studies and the implications of this 
work, and future studies. The citations from the general introduction and general conclusion 
chapters are included in the reference list at the end of this dissertation. 
LITERATURE REVIEW 
Basic swine immunology 
Defense mechanisms of swine against infectious pathogens are similar to those of 
other vertebrates and are comprised of an early non-specific response called innate immunity 
and a late specific response called adaptive immunity. Innate immunity is essential in 
controlling an infection during the first few days following exposure to pathogens. The innate 
immune system recognizes pathogens by their molecular patterns and the response is non­
specific against all types of infection. The principal components of innate immunity include 
(a) physical and chemical barriers such as integument and epithelial barriers; (b) phagocytic 
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cells such as neutrophils, macrophages, and natural killer (NK) cells; (c) blood proteins such 
as complement and inflammatory mediators; and (d) cytokines such as interferon (IFN) - a. 
In contrast to innate immunity, adaptive immunity responds more specifically to pathogens 
and is capable of recognizing individual pathogens resulting in immunological memory. 
Although the primary exposure to a pathogen takes longer to induce an adaptive immune 
response compared to innate immunity, a secondary response occurs more rapidly with 
subsequent exposures. The major components of the adaptive immune response are the 
humoral (HI) and cell-mediated (CMI) responses. The HI response is comprised of B cells 
that secrete antigen specific antibodies. Antibodies can neutralize the pathogen to prevent the 
attachment to host cells, opsonize the pathogen to enhance phagocytosis, and activate 
complement resulting in lysis of the microbe. In contrast, the CMI response is predominantly 
comprised of T helper (Th) and cytotoxic T (Tc) lymphocytes. Th cells are responsible for 
orchestrating and directing an immune response, whereas Tc cells are responsible for the 
killing and elimination of infected host cells. 
Lymphocyte subpopulation 
Lymphocyte subpopulations are defined by the expression of surface molecules, 
which are designated as "cluster of differentiation or CD molecules". According to the CD 
molecules, four major subpopulations of porcine lymphocytes have been described including 
CD4+CD8-, CD4-CD8+, CD4+CD8+, and CD4-CD8- T cells (Yang and Parkhouse, 1996; 
Saalmuller, 1998; Boeker et al., 1999; Terzic et al., 2002). 
An important subpopulation is CD4+CD8- T lymphocytes, known as Th cells. This 
subpopulation is involved in both HI and CMI responses and functions to facilitate the 
generation of antigen specific antibodies by B cells and to assist the CMI response. 
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CD4+CD8- T lymphocytes can further differentiate into 2 different types of Th cells, Thl 
and Th2 cells, based on their function and the cytokines produced. The differentiation of Th 
cells into Thl and Th2 cells, their specific functions and cytokine production are described in 
detail later. 
The second population consists of CD4-CD8+ T lymphocytes, also known as Tc 
cells. CD4-CD8+ T lymphocytes appear to be the principal defense mechanism against 
intracellular pathogens. The major function of this subpopulation of lymphocytes is to kill 
infected cells using two major mechanisms, the perforin granule exocytosis pathway and the 
FasL/Fas mechanism to induce apoptosis. In addition, it has been reported that this 
subpopulation is an early non-antigen-specific source of IFN-y (Kambayashi et al., 2003). 
Porcine CD4-CD8+ T lymphocytes contain two main subsets of lymphocytes, which can be 
further characterized according to their immunological functions (Saalmuller, 1998). The 
first subset of this subpopulation has a spontaneous non-MHC-restricted cytolytic function 
and expresses low amounts of CD8 on the surface (Saalmuller et al., 1994). The second 
subset has MHC class I restricted cytolytic activity and expresses high amount of CD8 on the 
surface. 
In contrast to other species, pigs have significant numbers of extra-thymic T 
lymphocytes that express both CD4 and CD8 on their surface. This finding appears to be 
very unique to the porcine immune system (Pescovitz et al., 1994; Zuckermann, 1999). This 
CD4+CD8+ double positive (DP) population in pigs is comprised predominantly of MHC 
class II restricted memory CD4+ T cells that following specific activation have acquired the 
ability to express CD8 on their surface and maintain the double positive phenotype 
(Zuckermann, 1999; Saalmuller et al., 2002). The CD4+CD8+ DP T cells have demonstrated 
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the ability to respond to recall antigen and the expression of memory T cell markers suggests 
a potential role as memory cells. In addition, this population produces higher levels of IFN-y 
in response to antigen stimulation than CD4+CD8- and CD4-CD8+ T cells and the 
proportion of these DP T cells increases with age (Zuckermann, 1999). 
Pigs have a higher population of T cells expressing neither CD4 nor CD8 (CD4-CD8-
T cells) compared to other mammals (Davis et al., 1998; Yang and Parkhouse, 2000). This 
population expresses the yô T-cell receptor (TCR), which differs from the first three 
subpopulations that express the a|3 TCR. It was reported that unlike aP T cells, the porcine 
yô T cells do not respond in an in vitro proliferative assay using anti-CD3 monoclonal 
antibodies to trigger TCR (Yang and Parkhouse, 2000). The functions and roles of these yô T 
cells are poorly understood and require further investigation. 
Th 1 and Th 2 paradigm 
CD4+CD8- T cells are involved in both HI and CMI responses by serving as 
intermediates between the antigen presenting cells, B cells, phagocytic cells, and 
lymphocytes. This Th cell subpopulation is able to differentiate into two subsets of cells 
called Thl and Th2 cells that are capable of directing and promoting different immune 
response pathways (Kidd, 2003). It is noteworthy that the Thl and Th2 hypothesis is 
primarily based on studies in mice and humans and there are some obvious dissimilarities 
between mouse, human and porcine T cells. Although the Thl and Th2 hypothesis in pigs 
remain to be further defined, there are a few studies demonstrating the presence of Thl and 
Th2 polarized T cells in pigs (Foss and Murtaugh, 1999b; Fischer et al., 2000). 
The differentiation of naïve CD4+CD8- T cells into Thl and Th2 cells is influenced 
by the cytokines produced early in the immune response (Abbas and Lichtman, 2003; Kidd, 
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2003). Production of IL-12 by dendritic cells appears to be a primary inducer of Thl cells, 
whereas IL-4 favors the differentiation of Th cells into Th2 cells. The Thl immune response 
is associated with a strong CMI response, which is mediated by phagocytic cells including 
macrophages and neutrophils, and cytotoxic T cells. This type of immune response is 
important in controlling infection caused by viruses and other intracellular pathogens. The 
Th2 immune response, however, is more closely associated with an HI response, which is 
mediated predominantly by B cells, ultimately resulting in the production of antibodies. 
Therefore, this type of immune response is important against many extracellular pathogens 
such as extracellular bacteria and helminthes. 
Both Thl and Th2 cells produce distinct sets of cytokines and perform different 
functions. An important cytokine produced by Thl cells is IFN-y, which functions in the 
activation of macrophages and neutrophils resulting in enhanced microbial clearance by 
macrophages. The activation of macrophages also induces the production of IL-12, which in 
turn further promotes the differentiation of Th cells into Thl cells, resulting in more the IFN-
Y production. IFN-y inhibits the proliferation of Th2 cells, thus further promoting Thl 
differentiation. Production of IL-12 and IFN-y also enhances the cytotoxicity of Tc and NK 
cells. The Thl cells are also able to stimulate B cells to produce opsonizing and complement 
fixing antibodies. In contrast to the cytokines produced by Thl cells, cytokines produced by 
Th2 cells consist primarily of IL-4, and IL-5. The Th2 cells also produce cytokines such as 
IL-10 and IL-13 that antagonize the action of IFN-y and suppress macrophage function 
resulting in the enhancement of the Th2 response. In addition, Th2 cells function to activate 
B cells to secrete specific antibodies and cause the proliferation of mast and eosinophilic 
cells. Less is known about this process in pigs and there is some evidence that IL-12 response 
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is inconsistent with the response observed in humans and mice (Domeika et al., 2002; 
Solano-Aguilar et al., 2002). 
Vaccines 
Vaccination involves inoculation of microorganisms or their products into the host 
body to induce an immune response against the pathogen. Vaccination has been performed 
for many decades to prevent and/or reduce infection and associated disease. The history of 
vaccination dates back thousand's of years to China, where material from a pustule of 
smallpox patients was intentionally inoculated into healthy people to induce immunity 
(Abbas and Lichtman, 2003). The technique called variolation was later introduced in Europe 
and became widely recognized as vaccination, when Edward Jenner demonstrated that a 
child inoculated with material from a cowpox lesion was protected against smallpox 
(Makela, 2000). After this discovery, vaccination against smallpox was rapidly accepted 
throughout Europe. However, it was not until nearly 100 years later, that vaccines against 
other pathogens were developed. 
Presently, several types of vaccines have been described including inactivated, 
attenuated by traditional methods, attenuated by genetic manipulation, subunit, and DNA 
vaccines. 
An inactivated or killed vaccine (KV) contains an organism that was inactivated by 
chemical agents to reduce or eliminate the pathogenicity without altering the immunogenicity 
of the proteins or epitopes responsible for induction of effective immune response. The 
infectious agent in inactivated vaccines can no longer replicate in the host body making them 
safer and often preferable to live organism vaccines. An inactivated vaccine may consist of 
whole or fractions of killed organisms, or chemically inactivated products such as toxins. 
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Normally, an adjuvant is required with an inactivated vaccine in order to induce protective 
immunity. An inactivated vaccine is usually administered by either intramuscular or 
subcutaneous routes and typically, two doses, at 2 to 6 weeks interval, are required to induce 
immunity. Following vaccination, an inactivated vaccine usually induces serum antibody 
titers, but is typically less effective in stimulating CMI and mucosal responses. 
Reticulating and alkylating agents are the two major chemical agents that have been 
used to inactivate the organism. Reticulating agents are aldehydes, with the most frequently 
used being formaldehyde. Betapropiolactone and binary ethyleneimine are examples of 
alkylating agents. Reticulating agents inactivate the organisms by cross-linking amide groups 
in the proteins with the hydrogen-bonded amino acid groups on the nucleic acid to confer 
structural rigidity, whereas the alkylating agents inactivate the organisms by cross-linking the 
nucleic acid chain (Twomey et al., 1995). 
An attenuated or modified live (MLV) vaccine is made up of an organism that has 
been attenuated to reduce or eliminate the pathogenicity without altering the immunogenicity 
of the proteins or epitopes required to induce an effective immune response. The attenuated 
organism remains capable of replication in the host cells. The attenuation process can be 
achieved by propagating infectious organisms under conditions different from those in the 
infected host and unfavorable to its growth such as repeated passages through abnormal hosts 
(different species) or culturing in cell lines at lower temperatures (Maassab and Bryant, 
1999). In addition, due to advances in molecular technologies, attenuation of infectious 
agents can also be achieved by the deletion of specific virulence genes. An example of a 
vaccine employing gene deletion is pseudorabies virus (PRV) vaccine (Mengeling et al., 
1997). Pseudorabies virus, an alpha herpesvirus of swine, has a number of genes that can be 
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deleted without altering its capability to replicate in vivo. However, such deletions change the 
virulence characteristics of the pathogen in vivo. Vaccination with the gene-deleted vaccines 
allows the differentiation of infected and vaccinated animals. The successful eradication of 
PRV is an excellent example of using a gene-deleted vaccine to remove naturally infected 
pigs from a vaccinated herd (Lehman et al., 1994; Van Oirschot et al., 1996). 
Generally, an attenuated vaccine does not require an adjuvant, however some 
attenuated vaccines may contain an adjuvant. An attenuated vaccine may take a shorter 
duration of time to induce an effective immune response compared to an inactivated vaccine. 
In addition, only a single dose of an attenuated vaccine is capable of inducing sufficient 
immunity. Besides parenteral routes, an attenuated vaccine can also be administered via 
intranasal and oral routes providing that the attenuated organisms sufficient replicate on 
mucosal surface or gain access to proper lymphoid tissues. 
An attenuated vaccine is generally more effective than an inactivated vaccine in 
inducing effective immune responses as both strong HI and CMI responses are observed. An 
inactivated vaccine usually induces production of antibodies, but is less effective in 
stimulating CMI response. An attenuated vaccine possesses attenuated pathogens, which are 
still capable of replication in host cells causing an infection that resembles a natural 
infection. The attenuated pathogen can be processed intracellularly so that antigens are 
presented by MHC class I molecule to CD8+ T cells resulting in the induction of an effective 
CMI response as well as HI response. In contrast, an inactivated vaccine contains killed 
pathogen incapable of replicating in host cells. The killed pathogen is primarily recognized as 
an extracellular antigen, which is taken up by antigen presenting cells (APCs) such as 
macrophages and dendritic cells, and is presented by the MHC class II molecules of APCs to 
CD4+ T cells resulting in the production of antibodies and the induction of CMI response via 
Th cells. It was demonstrated that an inactivated vaccine can activate the function of Tc cells 
via the process called cross-presentation, which is mediated by dendritic cells. Dendritic cells 
are able to capture and cross-present the extracellular antigens contained in the inactivated 
vaccine and present them to Tc cells via the MHC class I pathway (Moron et al., 2004; Storni 
and Bachmann, 2004). 
It is difficult to make a judgment as to which type of vaccine is better. Each vaccine 
type has both advantages and disadvantages. An inactivated vaccine is usually safer as it can 
not revert to virulence and cause disease compared to an attenuated vaccine, however, it is 
typically less effective in inducing an immune response. An attenuated vaccine, although, has 
increased efficacy, has several disadvantages. Inadequate attenuation can lead to reversion to 
virulence form. An attenuated vaccine has the potential of inducing disease in 
immunocompromised hosts. Furthermore, vaccine viruses can result in persistent infection as 
previously reported with some viral vaccines (Botner et al., 1994). 
Adjuvants and the use of cytokines as adjuvants 
Adjuvants have been defined as substances that enhance the immunogenicity of 
antigens in a vaccine resulting in increased immune responses. Many substances have been 
demonstrated to act as adjuvants including aluminium salts, water-in-oil emulsions, oil-in-
water emulsions, complete and incomplete Freund's adjuvants, and others (Van Oirschot, 
1997). Adjuvants can enhance the immunogenicity of antigens in different ways including 
depot generation and immunomodulation (Cox and Coulter, 1997; Schijns, 2002). Generation 
of a depot is an early theory used to describe action of some adjuvants. This theory is based 
on the thought that adjuvants allow small particulate antigens to be more readily ingested by 
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professional antigen presenting cells compared to large particles. In addition, minimal 
amounts of small antigenic particles are released over a prolonged period resulting in 
sustained T cell activation. Adjuvants such as aluminum salts are included in this category. 
Immunomodulatory effects are considered another mode of action based on the ability of 
adjuvants to induce the production of pro-inflammatory cytokines and a local inflammatory 
response resulting in up-regulation of the innate and adaptive immune responses. Aluminum 
salts and bacterial antigens are examples of this type of aduvant. 
Several cytokines such as IFN- y, IL-2, IL-4, and IL-12 have been studied intensively 
for their potential use as adjuvants due to their immunomodulatory effects (Schijns et al., 
1994; Dittmer et al., 2001; Min et al., 2001). Among these cytokines, IL-12 has been 
demonstrated to enhance the CMI response in mice and humans, which suggested it may 
have potential use as an adjuvant used with vaccines against intracellular pathogens (Park 
and Scott, 2001). 
Interleukin-12 is heterodimeric protein. The bioactive form of IL-12 consists of 35 
and 40 kDa proteins (Trinchieri and Scott, 1995; Foss et al., 1999). The two subunits of IL-
12 are covalently linked by a single disulfide bond to form the active protein. While the p35 
subunit is constitutively expressed, the p40 subunit is expressed only in response to various 
stimuli. The production of p40 in excess of p35 can result in formation of p80 homodimers 
that antagonize the activity of the IL-12 heterodimer. Interleukin-12 is produced by antigen 
presenting cells (APCs) such as dendritic cells, macrophages, and monocytes in response to 
infection by bacteria, intracellular parasites and viruses. Interleukin-12 plays an important 
role in the induction of a CMI response. It enhances the cytolytic activity of Tc lymphocytes 
and NK cells and is involved in the differentiation of ThO cells to the Thl subset by acting 
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directly on CD4+ T-lymphocytes to inhibit the production of IL-4 (Seder et al., 1993). The 
production of Th 1 cells is important for the elimination of virus-infected cells and cells that 
are infected by intracellular pathogens. In addition, IL-12 promotes IFN-y production (Seder 
et al., 1993; Trinchieri and Scott, 1995). 
Due to the potent immunoregulatory properties of IL-12 that stimulate antigen-
specific Thl cells and cytotoxic activity, it has been studied by several investigators as a 
potential adjuvant for enhancing the efficacy of vaccines against intracellular pathogens in 
human, mice and pigs (Afonso et al., 1994; Kincy-Cain et al., 1996; Zuckermann et al., 1998; 
Buchanan et al., 2001). One of the first studies that demonstrated the adjuvant activity of IL-
12 was reported by Afonso et al. (1994). In this study, vaccination of mice with Leishmania 
antigens in conjunction with IL-12 increased the number of Leishmania specific Thl cells 
that were required to protect against Leishmaniasis. In addition, vaccinated mice were 
resistant to subsequent Leishmania challenge. In pigs, the use of IL-12 as an adjuvant has 
also been investigated (Zuckermann et al., 1998). A study demonstrated no difference in 
neutralizing antibodies in pigs vaccinated with pseudorabies virus vaccine co-administrated 
with IL-12. However, the number of virus specific IFN-y secreting cells was significantly 
increased in the vaccinated group receiving IL-12. The results of this study suggest that IL-
12 may be effective as an adjuvant in for swine vaccines. 
Currently, there are both MLV and KV PRRSV vaccines available. However, the 
efficacy of both vaccines is difficult to define. In addition, MLV PRRSV vaccine mimics 
infection resulting in the shedding of vaccine virus. KV PRRSV vaccine does not induce 
detectable levels of antibodies suggesting the need for enhancing the immunogenicity of this 
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vaccine. In the studies reported here, we investigated the immunological impact of adding 
IL-12 to a PRRSV KV. 
Porcine reproductive and respiratory syndrome 
In the late 1980's, a swine disease of unknown etiology characterized by reproductive 
and respiratory disease was reported in the swine producing regions of North America 
(Keffaber, 1989; Hill, 1990) and Canada (Dea et al., 1992). A similar syndrome was reported 
in Europe in June, 1990, where the disease affected more than 80% of herds in Germany 
(Meredith, 1995). The disease appeared to spread through Europe including in the 
Netherlands, Denmark, England and France soon after discovery (Baron et al., 1992; Botner 
et al., 1994). 
The causative agent of the mystery disease remained unidentified until 1991, when 
researchers in Lelystad, The Netherlands, isolated a virus from infected pigs using porcine 
alveolar macrophages. The virus was later called the Lelystad virus (LV) (Wensvoort et al., 
1991) and Koch's postulates were fulfilled when pre-weaning pigs and pregnant sows 
challenged experimentally with the LV developed a syndrome resembling the mystery swine 
disease (Terpstra et al., 1991; Wensvoort et al., 1991). Soon after its discovery in the 
Netherlands, LV was isolated in several countries throughout Europe. Although the virus was 
not isolated in some countries, specific antibodies against the LV were detected in pigs with 
mystery disease. In the U.S., the causative agent of the mystery disease was successfully 
isolated in 1992 from affected tissues of infected piglets obtained from farms experiencing 
clinical signs of the disease (Collins et al., 1992). The virus was submitted to the American 
Type Culture Collection as VR-2332 (ATCC VR-2332), and named "swine infertility and 
respiratory syndrome" (SIRS) virus (Goyal, 1993). 
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After the causative agent was identified for this syndrome, the name "porcine 
reproductive and respiratory syndrome virus" (PRRSV) was adopted at the First International 
Symposium on SIRS/PRRS in Minnesota, U.S.A. (Goyal, 1993). At this meeting, the name 
porcine reproductive and respiratory syndrome (PRRS) was adopted internationally as the 
clinical syndrome characterized by reproductive disorders in female pigs and respiratory 
disease, including pneumonia in younger pigs. 
Porcine reproductive and respiratory syndrome virus has been assigned to the genus 
Arterivirus, family Arteriviridae of the order Nidovirales (Cavanagh, 1997). Members of this 
virus family include lactate dehydrogenase-elevating virus (LDV), equine arteritis virus 
(EAV) and simian haemorrhagic fever virus (SHFV). Serological cross-reaction was not 
found between PRRSV and other arteriviruses or coronaviruses (Wensvoort et al., 1992). 
Genomic studies have revealed that there are two distinct genotypes of PRRSV which 
represent the prototypes of the North American and the European isolates (Meng et al., 
1995a; Meng et al., 1995b; Murtaugh et al., 1995; Nelsen et al., 1999). Both isolates are 
similar in morphology, structure, and organization of the genome. 
Genomic organization 
Porcine reproductive and respiratory syndrome virus is an enveloped positive-sense 
single-stranded RNA virus, which is approximately 15 kilobases in length. The virus has a 
similar genomic organization as other arteriviruses. Eight open reading frames (ORFs) 
designated as ORFs 1 through 7 have been identified (Meulenberg et al., 1997). Open 
reading frame 1, further divided into ORFs la and lb, comprises approximately 80% of the 
genome and encodes the viral dependent RNA polymerase. The other 6 ORFs (ORFs 2-7) 
encode six structural proteins. The ORFs 2 through 5 of PRRSV encode glycoproteins (GP) 2 
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through 5, which are glycosylated proteins and located in the viral envelope. Glycoprotein 3 
has the highest degree of glycosylation compared to the other glycoproteins (Gonin et al., 
1998). The ORF5 of PRRSV is the most variable region (Murtaugh et al., 1998) and appears 
to be associated with neutralizing epitopes (Gonin et al., 1999; Weiland et al., 1999; 
Plagemann et al., 2002; Wissink et al., 2003). The ORF6 is the most conserved region of 
PRRSV (Kapur et al., 1996) and encodes the matrix (M) protein. The ORF 7 encodes the 
nucleocapsid (N) protein. It has been demonstrated that the N protein is the most 
immunodominant protein (Nelson et al., 1994). 
Pathogenesis of PRRSV 
The primary route of transmission of PRRSV is direct contact. The virus typically 
enters the host through the respiratory tract. Once in the pig, PRRSV replicates primarily in 
pulmonary alveolar macrophages (PAMs). Pulmonary intravascular macrophages (PIMs) and 
macrophages of other tissues, including dendritic cells can support the replication of virus as 
well (Halbur et al., 1996a; Thanawongnuwech et al., 2000). In vitro studies demonstrated that 
internalization of virus by PAMs occurs by receptor mediated endocytosis (Nauwynck et al., 
1999), and a sialoadhesin has been shown to serve as a receptor (Vanderheijden et al., 2003). 
Following primary replication, the virus is transported from the lung as cell-free or cell-
associated virus to secondary lymphoid tissues including tonsil, spleen and lymph nodes. 
Infected pigs become viremic following exposure to virus and PRRSV can be 
detected in the serum of infected pigs as early as 12-24 hours post exposure. The virus can be 
found in heart, thymus, spleen, brain, testes and ovaries (Rossow et al., 1994; Halbur et al., 
1996a; Rossow et al., 1996; Duan et al., 1997; Sur et al., 1997; Thanawongnuwech et al., 
1997; Sur et al., 2001). Virus shedding occurs from many sites including saliva, nasal 
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secretions, urine, semen, feces and mammary secretions and the shedding is believed to be 
intermittent (Rossow et al., 1994; Wills et al., 1997; Wagstrom et al., 2001). 
PRRSV causes a persistent infection. The first evidence of persistent infection was 
demonstrated when an experimentally infected sow transmitted the virus to 3 sentinel pigs up 
to 99 days post infection (DPI) (Zimmerman et al., 1992). Subsequently, Albina et al. (1994) 
found that PRRSV-negative pigs became infected with the virus when commingled with pigs 
infected 154 days previously. To date, it remains unknown how long infected pigs can carry 
the virus. Benfield et al. (1997) demonstrated that virus RNA was detected by PGR for up to 
210 days post partum in pigs farrowed from gilts exposed to PRRSV during late gestation. In 
another study, the virus was isolated from oropharyngeal scrapings from experimentally 
infected pigs up to 157 DPI (Wills et al., 1997). It was demonstrated that 100% of 
experimentally infected pigs carried PRRSV for 63 DPI (Horter et al., 2002) and the carrier 
rate was still at 90% by 105 DPI. Although PRRSV causes a persistent infection, it appears 
that the virus does not seem to persist for the life of pigs. It has been suggested that the virus 
is eliminated from the body of infected animals by 150 DPI or shortly thereafter (Allende et 
al., 2000). The mechanism of persistent infection is not clearly understood. However, the 
detection of viral RNA during the chronic phase of infection in tonsils suggest they may be a 
possible site of persistent infection. This hypothesis is supported by several reports of viral 
isolation from tonsil and a recent field observation, which demonstrated that oropharyngeal 
scraping samples from aviremic, clinically normal and seronegative sows were PGR positive 
for PRRSV RNA (Kleiboeker et al., 2002). 
Macroscopic and microscopic lesions associated with PRRSV infection have been 
characterized by a number of investigators using various PRRSV isolates (Rossow et al., 
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1994; Halbur et al., 1995; Halbur et al., 1996b; Rossow et al., 1996). Macroscopic lung 
lesions vary from none to diffuse consolidation depending on the PRRSV isolate used. The 
affected lobes are mottled and diffusely tan in color. Interstitial pneumonia is the most 
common form of lung lesion observed in both naturally and experimentally infected pigs. 
Microscopic lung lesions are characterized by a thickening of the alveolar septa with 
infiltration of macrophages and mononuclear cells. Necrotic cells and dead cell debris are 
also observed in the alveoli. The lymph nodes of both naturally and experimentally infected 
pigs are markedly enlarged. The microscopic lesions in the lymph nodes are characterized by 
germinal center hypertrophy and hyperplasia, and necrosis of the germinal centers. Lymph 
node lesions in pigs infected in utero are characterized by cell necrosis, and germinal center 
cell hypertrophy and hyperplasia. Follicular hypertrophy is observed in tonsils and Peyer's 
patches. Vasculitis is observed in vessels of all sizes and is characterized by an infiltration of 
macrophages, lymphocytes and mononuclear cells. Infiltration of lymphocytes and 
mononuclear cells is observed in the heart and brain lesions, and causes myocarditis and 
meningoencephalitis. The virus is also found in microglia and neurons of brains in infected 
pigs, especially young pigs (Thanawongnuwech et al., 1997; Rossow et al., 1999). 
PRRSV induces apoptosis following infection (Sur et al., 1996; Sirinarumitr et al., 
1998; Sur et al., 1998; Suarez, 2000). The ORF5 product of PRRSV was demonstrated to 
induce apoptosis in infected cells (Suarez et al., 1996). Apoptosis was detected 
predominantly in mononuclear cells, PAMs, and PIMs of lungs, and macrophages in lymph 
nodes of infected pigs. The PRRSV-induced apoptosis was also demonstrated in testicular 
epithelial germ cells of infected boars (Sur et al., 1997). The majority of apoptotic cells were 
uninfected bystander cells suggesting an indirect mechanism induced by PRRSV as the cause 
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of apoptosis (Sirinarumitr et al., 1998). The mechanism of apoptosis induced by PRRSV 
infection is still unknown and apoptosis has been suggested as a host response to prevent 
further infection and to reduce the number of PAMs susceptible to infection or part of the 
pathogenesis associated with PRRSV. 
Responses of the host following PRRSV infection 
Immune response 
Pigs develop both HI and CMI responses against PRRSV following infection. The HI 
response can be measured using several assays, including indirect fluorescent assay (IFA), an 
immunoperoxidase monolayer assay (IPMA), enzyme-linked immunosorbent assay (ELISA), 
and serum neutralizing antibody assay (SN) (Nelson et al., 1994; Yoon et al., 1995; Loemba 
et al., 1996; Albina et al., 1998b). The CMI response is measured by lymphocyte 
proliferation assays and enumeration of PRRSV specific IFN-y producing cells using an 
enzyme-linked immuno spot assay (ELISPOT) (Albina et al., 1994; Vezina et al., 1996; 
Lopez Fuertes et al., 1999; Meier et al., 2003). 
Humoral immune response 
Several investigators have studied the kinetics of the HI response against PRRSV 
(Nelson et al., 1994; Loemba et al., 1996; Yoon et al., 1996) and demonstrated that PRRSV 
specific antibodies can be first detected as early as 5 to 7 DPI. The earliest isotype of 
antibodies detected in serum are immunoglobulin (Ig) M, with PRRSV specific IgM first 
detected by IF A as early as 5-7 DPI (Park et al., 1995). The PRRSV specific IgM peaks at 9-
10 DPI and begins decreasing at 14-21 DPI becoming undetectable by 35-42 DPI. PRRSV 
specific IgG is first be detected by IPMA at 5-9 DPI and reaches maximal levels by 28-42 
DPI. Yoon et al. (1995) detected PRRSV antibodies by IF A, ELISA and SN at 9-11, 9-13 
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and 9-28 DPI, respectively and the antibody titers reached maximum levels by 28-35, 35-42, 
and 77-84 DPI. Once the highest level was reached, the antibody levels assayed by all four 
serological tests declined. Statistical calculation by logistic regression analysis estimated that 
the antibody titers detected by ELISA, IF A, IPMA and SN would disappear by 
approximately 137, 158, 324 and 356 DPI. It is interesting to note that the production of 
antibodies is generally observed within a week or two following infection are not associated 
with protection. Antibodies associated with protection, including SN antibodies, become 
detectable 4 to 6 weeks post infection, suggesting that the development of an effective 
antibody response is delayed following PRRSV infection. 
The initial PRRSV antibody response detected within a week or two of infection is 
directed against the N protein (Nelson et al., 1994). The N protein is considered to be an 
immunodominant protein due to the strong signal observed by immunoblot assay during the 
first few weeks after exposure (Nelson et al., 1994; Loemba et al., 1996). An association 
between the N protein and viral neutralizing antibodies has not been demonstrated (Nelson et 
al., 1994; Yoon et al., 1995; Loemba et al., 1996; Vezina et al., 1996). Studies of the 
antibody responses towards the structural proteins N, M, and GP5 by immunoblotting assays 
have yielded variable results (Nelson et al., 1994; Yoon et al., 1995; Loemba et al., 1996). 
While the antibody response detected at 7 DPI was directed against the N protein, the 
antibody response detected at 14 DPI was directed against both the N and M proteins 
(Loemba et al., 1996). Other studies revealed that seroreactivity to GP5 is generally observed 
by 21-28 DPI (Nelson et al., 1994; Yoon et al., 1995), which coincides with the development 
of SN antibodies. It was demonstrated that the ectodomain of GP5 of PRRSV contains the 
primary neutralizing epitope (Plagemann, 2003; Plagemann, 2004). 
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Cell-mediated immune response 
The CMI response in pigs following PRRSV infection as measured by PRRSV-
specific lymphocyte proliferation assays can first be detected at 28 DPI and persists for more 
than 3 months (Bautista and Molitor, 1997; Lopez Fuertes et al., 1999). The CMI response 
approaches a maximum level at 49 DPI. The lymphocyte proliferation was antigen-specific 
and dose-dependent (Bautista and Molitor, 1997). An in vitro study of cultured T cells 
demonstrated that the CMI response was primarily due to the proliferation of CD4+CD8+ 
and CD8+ cells subsets. In this study, infected pigs were rechallenged with the same PRRSV 
isolate 20 weeks post primary infection and an anamnestic response of T-cell proliferation 
was detected within one week after rechallenge, however it lasted only 3 weeks (Bautista and 
Molitor, 1997). 
Cell-mediated immunity has also been studied using an enzyme-linked immuno spot 
assay (ELISPOT) (Meier et al., 2003). This assay enumerates PRRSV specific interferon 
(IFN)- y secreting cells and appears to be directly proportional to the CMI response 
(Zuckermann et al., 1998). Interestingly, PRRSV specific IFN-y producing cells were not 
detected until 9-10 weeks after infection in comparison with the production of specific IFN-y 
secreting cells against pseudorabies virus (PRV), which were detected within 2 weeks post 
infection. The study also found that it took more than 30 weeks after infection for the number 
of PRRSV specific IFN-y producing cells to reach an equivalent level that the PRV specific 
IFN-y response attained by 2 weeks after vaccination (Meier et al., 2003). However, the slow 
development of IFN-y producing cells found in this study might represent only the systemic 
response following infection, whereas the local response in the respiratory tract may occur 
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earlier, as it was demonstrated that a significant level of IFN-y was detected in the lungs of 
PRRSV infected pigs at 10 DPI (Thanawongnuwech and Thacker, 2003). 
PRRSV structural proteins differ in their ability to elicit a CMI response (Bautista et 
al., 1999). Peripheral blood mononuclear cells were collected from infected pigs and assayed 
for CMI response by lymphocyte histogenesis response and delayed-type hypersensitivity 
assays using individual purified structural proteins of PRRSV including N, M, GP2, GP4 and 
GP5 proteins obtained from a vaccinia virus expression system. The lowest lymphocyte 
proliferative response was observed when the PBMCs were restimulated with nucleocapsid 
protein. Moderate proliferative responses were observed to GP5, GP2 and GP4 proteins. The 
greatest proliferative responses were observed when the M protein was used suggesting that 
this protein may play a role in the induction of CMI response. 
During early PRRSV infection, a change in cell populations in bronchoalveolar 
lavage (BAL) fluid occured. Total cell numbers in the BAL of infected pigs increased two to 
five times from 9 to 25 DPI due to the influx of monocytes and macrophages (Labarque et 
al., 2000). This influx of new monocytes and macrophages during early infection appears to 
replace the reduced number of differentiated macrophages that were destroyed by PRRSV or 
apoptosis. There is strong evidence suggesting that the increase in cells may be due to an 
influx of lymphocytic cells with a phenotype associated with natural killer cells and cytotoxic 
T cells (Samsom et al., 2000). 
Changes in the lymphocyte populations in peripheral blood mononuclear cells were 
observed in pigs infected with PRRSV (Shimizu et al., 1996). The total number of 
lymphocytes markedly decreased after infection. A decline in the number of CD4+ T cells 
was observed until 14 DPI, after which normal levels returned. The number of CD8+ T cells 
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decreased slightly until 3 DPI and then increased by 28 to 35 DPI. Thus, the ratio of CD4+ 
/CD8+ T cells decreased during the acute and chronic phases of PRRSV infection. The 
decreased ratio during acute infection was due to a decrease in CD4+ T cells, while an 
increase of CD8+ T cells during the chronic phase of infection led to an equivalent ratio. 
Similarly, in a second study, a decrease of CD4+ T cells and an increase of CD8+ T cells 
following infection were reported (Albina et al., 1998b). Since CD4+ and CD8+ T cells are 
not susceptible to PRRSV infection, the mechanism involved in the alteration of T cell 
population may be indirect and regulated by cytokines such as IL-10 (Lopez Fuertes et al., 
1999; Thanawongnuwech and Thacker, 2003). 
PRRSV infection induces a polyclonal activation of B cells following infection 
(Lamontagne et al., 2001; Lemke et al., 2004). Percentages of B cells increase in the tonsils 
and spleens of infected pigs as soon as 3 DPI due to an increase in IgG producing B cells 
(Lamontagne et al., 2001). The number of B cells also increase in peripheral blood, lymph 
nodes and Peyer's Patch (Kawashima et al., 1999). The polyclonal activation of B cells is 
associated with elevated levels of serum immunoglobulin, lymphoid hyperplasia, and 
formation of immune complexes. All of these changes contribute to the observed immune 
dysregulation associated with PRRSV infection (Lemke et al., 2004). 
Cytokine response 
PRRSV has a modulatory effect on a number of cytokines following infection. The 
first evidence of cytokine modulation by PRRSV was demonstrated when suppression of 
IFN-a production was observed in the serum and BAL of PRRSV infected pigs (Albina et 
al., 1998a). IFN-a production is an early cytokine response against viral infection resulting in 
the inhibition of viral replication in host cells. Although the serum of infected pigs contained 
25 
IFN-a in relatively low concentrations, most infected pigs had no IFN-a in their lung 
secretions. In vitro results from the same study had similar findings with neither PAMs nor 
PBMCs producing IFN-a in response to infection. Although macrophages infected with 
PRRSV were co-infected with swine transmissible gastroenteritis virus, a known inducer of 
IFN-a, no IFN-a was detected. However, this suppressive effect was lost when PRRSV was 
inactivated. The results of this study suggest that PRRSV actively suppresses IFN-a 
production. The suppression of IFN-a production by PRRSV was also demonstrated in a 
second study when the production of IFN-a was minimally detectable in BAL following 
PRRSV infection (Van Reeth et al., 1999). The effect of IFN-a on PRRSV replication was 
also explored and it was demonstrated that PRRSV replication was reduced in cultured 
PAMs pretreated with exogenous IFN-a (Buddaert et al., 1998). The suppression of IFN-a 
production may play an important role in facilitating the replication and survival of PRRSV 
in the host cells. 
The effect of PRRSV on the production of the proinflammatory cytokines including 
IL-1, IL-6, IL-8 and TNF-a has also been investigated and it was found that only substantial 
amounts IL-1 were detected following PRRSV infection (Van Reeth et al., 1999). However, 
this finding was in contrast with a PRRSV and Mycoplasma hyopneumoniae co-infection 
study where PRRSV infected pigs demonstrated an increased expression of IL-la, IL-1 P, 
and IL-8 mRNA (Thanawongnuwech et al., 2001). TNF-a is rarely detectable following 
PRRSV infection (Van Reeth et al., 1999; Lopez-Fuertes et al., 2000). 
Recently, several studies demonstrated increased levels of IL-10 mRNA expression in 
PAMs and lymphocytes following PRRSV infection (Suradhat and Thanawongnuwech, 
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2003; Suradhat et al., 2003; Thanawongnuwech and Thacker, 2003), which suggests the 
immunomodulatory effect of PRRSV on the host immune system involving the production of 
cytokines associated with the balance of Thl and Th2 responses. The increased levels of IL-
10 might direct the immune response from a Thl response towards a less effective Th2 
response. 
Increased levels of IFN-y, indicative of a Thl response, were also demonstrated in the 
BAL of infected pigs early in infection (Thanawongnuwech and Thacker, 2003). The 
production of IFN-y was not associated with the elimination of PRRSV in infected lungs 
since the virus persisted in the face of IFN-y production. The local production of IFN-y did 
not reflect the systemic production of IFN-y, where detectable levels were not observed until 
late infection, 9-10 weeks post infection (Meier et al., 2003). 
Protective immunity conferred by natural infection and vaccination 
The development of protective immunity to PRRSV infection has been studied by 
numerous investigators in association with both natural and experimental infection. 
Protective immunity was first detected in field observations when PRRSV infected sows 
delivered normal litter sizes following rebreeding despite virus circulation on the farm 
(Albina et al., 1994; Bilodeau et al., 1994). In an experimental setting, previous exposure of 
pigs to PRRSV prevented the development of clinical signs and reduced the magnitude of 
viral shedding after subsequent rechallenge with PRRSV (Shibata et al., 2000). These 
observations suggested that PRRSV infected pigs can develop protective immunity following 
infection. 
Complete protection was demonstrated following rechallenge of previously infected 
pigs with the same isolate of PRRSV (Lager et al., 1997a; Lager et al., 1997b). In this study, 
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pregnant gilts were first exposed to the virus on either day 1 or day 30 of gestation and then 
rechallenged with homologous PRRSV on day 90 of gestation. Pregnant gilts in the challenge 
control group were exposed to the virus at day 90 of gestation. Transplacental infection was 
used to measure protective immunity. Transplacental infection and reproductive losses were 
not observed in gilts that had previously been infected and then rechallenged with the same 
strain of PRRSV. In contrast, transplacental infection and reproductive losses occurred in the 
pregnant gilts in the challenge control group. These findings suggest that gilts developed 
protective immunity against the homologous strain. The duration of protective immunity 
against the same PRRSV isolate was investigated (Lager et al., 1997a). In this study, infected 
gilts were bred at selected times (143 to 514 days) after primary virus exposure and were 
rechallenged for a second time to the homologous isolate at approximately 90 days of 
gestation. Virus was not detected in the BAL samples of dams or sera of piglets. These 
results of this trial suggest that the protective immunity against the homologous isolate lasted 
up to 604 DPI. Complete homologous protection from the reproductive effects of PRRSV 
was also observed in pigs vaccinated with MLV and rechallenged with the same vaccine 
virus at 120-140 days after vaccination (Gorcyca et al., 1997; Hesse et al., 1997). 
It was demonstrated that infected pigs could develop complete protection against 
homologous isolates of PRRSV (Lager et al., 1997a; Lager et al., 1997b). However, the 
results of recent studies demonstrated that the homologous protection may not always be 
complete. Reinfection with a homologous strain of PRRSV was shown to occur when pigs 
were challenged on day 0 and rechallenged with a homologous isolate on 77 DPI, and 
subsequently become re-infected (Shibata et al., 2000). Although the pigs did not develop 
clinical signs, viremia was detected 3 days after rechallenge. The viremia was lower in 
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magnitude and shorter in duration compared to control pigs, and no virus was isolated from 
any tissue at necropsies on 14 and 28 days post rechallenge. Similar findings of incomplete 
homologous protection were reported recently (McCaw et al., 2003). In this study, pigs were 
injected intramuscularly with wild-type PRRSV six times within 8 months and challenged 
intranasally with the same PRRSV isolate 4 months after the last injection. The virus was 
detected in 30 - 50% of rechallenged pigs demonstrating incomplete homologous protection. 
Heterologous protection is often less complete and may be of shorter duration 
compared to homologous protection. In a study, gilts were inoculated by the intrauterine 
route with PRRSV isolate NADC-8 and rechallenged oronasally with either homologous 
virus or an antigenically distinct LV isolate at 90 days of gestation (Lager et al., 1999). Gilts 
were necropised on 21 days post rechallenge. The interval between challenge and rechallenge 
varied from 134 to 170 days. With the heterologous challenge, virus was isolated from the 
tissues of necropsied gilts and the serum of fetuses suggesting incomplete protection. This 
was in contrast to another group of gilts rechallenged with the homologous PRRSV strain 
NADC-8, where complete protection was observed and the virus was not isolated from any 
gilt or piglet. 
Heterologous protection may be related to the challenge dose. Gilts vaccinated with a 
commercial PRRSV MLV prior to breeding were subsequently rechallenged with PRRSV 
strain NADC-8 at three different doses on day 90 of gestation (Benson et al., 2001). 
Transplacental infection did not occur in gilts challenged with a low dose of virus (102 
TCIDso/ml), whereas infection was exhibited in all gilts challenged with 104 TCID5o/ml and 
106 TCIDso/ml of the virus. These observations suggest that protection may be somewhat 
dose-dependent. 
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Maternal antibody protection 
Piglets obtain maternal antibodies via the colostrum, which in general provides 
protection against many infectious agents. However, little is known about the role of 
maternally derived antibodies (MDA) in PRRSV infection and the potential for protection. 
Antibodies specific to PRRSV have been demonstrated in colostrum collected from both 
experimentally and field infected sows (Albina et al., 1994; Nodelijk et al., 1997). Albina et 
al. (1994) reported that passive maternal immunity could be detected in the serum of pigs 
tested 4 days after farrowing from PRRSV infected sows and disappeared by 3 weeks of age. 
Another study demonstrated MDA could persist in the serum of piglets for as long as 4 to 10 
weeks of age (Nodelijk et al., 1997). However, the percentage of pigs with MDA at 10 weeks 
of age was very low. The MDA specific for PRRSV have a shorter duration compared to 
MDA specific to other swine diseases such as swine influenza virus. Furthermore, the 
presence of MDA in serum of piglets has been shown to be inconsistent within litters. In 
some instances, no MDA was detected in the sera of pigs farrowed from infected dams. The 
mean half-life of MDA to PRRSV was estimated to be 16.2 days (95% confidence interval: 
13.7 - 18.7 days) as detected by ELISA and 8.1 days (95% confidence interval: 6.3 - 10.0 
days) for SN antibodies (Senn et al., 1998). 
Maternal immunity can provide piglets some level of protection from infection in 
addition to protection against clinical disease. With PRRSV infection, the role of MDA in 
PRRSV protection is still questionable. There are a limited number of reports regarding the 
protection conferred by MDA from either natural infected or vaccinated dams. Early 
evidence of protection conferred by MDA in pigs farrowed from PRRSV vaccinated sows 
was demonstrated by reduced duration and magnitude of viremia, reduced febrile days and 
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improved weight gain (Gorcyca et al., 1996). Although the results of that study demonstrated 
that MDA may impact piglet health and the course of viremia, several later studies suggest 
that MDA specific to PRRSV appear to play a limited role in protection. Furthermore, there 
have been several reports of enhanced infection and replication of PRRSV in pigs with low 
levels of MDA (Yoon et al., 1996; Shibata et al., 1998). Therefore, the protection conferred 
by PRRSV specific MDA appears dependent on several factors including minimum 
challenge dose and the level of MDA present at the time of challenge. It was suggested that 
the minimum challenge dose necessary to infect pigs without MDA is < 102 2 TCID50 and > 
103 2 TCID50 for pigs with MDA (Morrison et al., 1996). The levels of MDA were not 
described in the study. The results of this study demonstrate that the protective capabilities of 
MDA need to be further investigated as many questions remain. 
Vaccines 
Both MLV and KV PRRSV vaccines are commercially available. Currently, Ingelvac 
RespPRRS/Repro® and Ingelvac PRRS ATP® are MLV vaccines and PRRomiSe® is a KV 
vaccine. The Ingelvac RespPRRS/Repro® was the first MLV marketed in 1994. The label 
recommendation is for use in 3-18 week-old pigs and non-pregnant females. An efficacy 
study demonstrated vaccinated gilts were not viremic following homologous or heterologous 
challenge. Vaccinated and challenged gilts also farrowed more live healthy piglets than non-
vaccinated and challenged gilts (Gorcyca et al., 1997). This MLV is derived from the 
PRRSV parent strain ATCC VR-2332 and was attenuated through repeated passage in cell 
culture. Only the amino acid sequence of ORF5 was compared and it was demonstrated that 
the ORF5 of vaccine virus differs from its parent strain at amino acid residues 13 and 151 
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(Wesley et al., 1999). The parent strain has an arginine at both positions, but the vaccine 
virus has a glutamine and a glycine at residue 13 and 151, respectively. 
Ingelvac® PRRS ATP, PRRS MLV vaccine was marketed in 1999. This vaccine was 
developed by the attenuation of a recently isolated, "atypical" or severe, PRRSV parent 
strain. The ecommendation is for the use in healthy, susceptible swine 3 weeks of age or 
older, up to 18 weeks of age, as an aid in the reduction of symptoms associated with 
respiratory disease. It was demonstrated that the vaccine reduced the severity of PRRS-
induced pneumonia following the challenge with three highly virulent heterologous 
challenges compared to the non-vaccinates (Opriessnig et al., 2002). 
PRRomiSe® KV is recommended for use in dams 5-8 weeks after breeding, followed 
by a second dose 14-28 days later. The KV contains inactivated PRRSV isolate VR-2402 
(originally designated as VR-2402) at low passage with a proprietary adjuvant. An efficacy 
study demonstrated that vaccinated gilts were not viremic following homologous challenge 
(Christensen et al., 1998). The number of viable pigs born to vaccinated gilts was 
significantly greater than those of pigs born from non-vaccinated gilts. 
Regardless of the type of vaccine, there is considerable controversy over PRRSV 
vaccine efficacy. The PRRSV vaccines, either MLV or KV, induce lower levels of immunity 
compared to vaccines against many other swine diseases. It took 4 to 5 weeks post 
vaccination for MLV vaccinated pigs to develop detectable levels of SN antibodies and IFN-
Y producing lymphocytes were not detected until 9 to 10 weeks post vaccination (Meier et al., 
2003). Furthermore, PRRSV MLV vaccines contain live virus. Vaccinated pigs may spread 
the vaccine virus to non-vaccinated pigs. Outbreaks of PRRSV in Denmark were attributed to 
the use of an "American strain" MLV where vaccinated pigs shed vaccine virus, including 
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boars in studs, resulting in PRRSV disease in susceptible pigs that were exposed directly or 
by semen (Botner et al., 1997). The vaccine virus reportedly can be shed from vaccinated 
pigs for at least 92 days after vaccination (Yaeger et al., 1993; Christopher-Hennings et al., 
1995; Christopher-Hennings et al., 1997). It has been reported the transmission of vaccine 
virus from MLV vaccinated pigs to naïve pigs can occur up to 36 days after vaccination 
(Torrison et al., 1996). The efficacy of killed vaccines has also been questioned. Several 
studies demonstrate that the killed vaccine induces poor antibody responses in PRRSV naïve 
pigs with no detectable antibodies measured by ELISA or SN assays. However, Bassaganya-
Riera et al. (2004) reported that although there were no detectable antibodies, a CMI 
response as measured by the proliferative response of CD8+ T cells was detected in naïve 
sows vaccinated with KV alone at 27 and 38 days post vaccination. 
Research on new generation of PRRSV vaccines 
Attempts to develop a new generation of PRRSV vaccines based on molecular 
technologies have been attempted by several investigators. The PRRSV proteins expressed in 
insect cells using a baculovirus system have been evaluated as potential subunit vaccines 
(Plana Duran et al., 1997). The ORFs 2-7 of PRRSV were inserted into recombinant 
baculoviruses. However, only ORFs 2, 3, 5 and 7 representing GP 2, 3, 5 and the N proteins, 
respectively were successfully expressed. To analyze their ability to confer protection, each 
of those recombinant proteins were adjuvanted and used for sow immunization. Some level 
of protection was observed in sows immunized with recombinant baculoviruses expressing 
the products of ORFs 3 and 5 as they successfully weaned 68.5% and 50%, respectively, 
healthy piglets following challenge. In contrast, non-immunized control sows and sows 
immunized with recombinant baculoviruses expressing the products of ORFs 2 weaned only 
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12.6% and 16.6% of healthy pigs. These results suggested that ORFs 3 and 5 may be 
involved in the induction of protective immunity and have potential use as vaccine 
candidates. 
Genomic regions encoding for ORFs 4 to 7 were studied to determine their potential 
use in DNA vaccines by cloning into a mammalian expression vector (Kwang et al., 1999). 
Pigs were injected intramuscularly with DNA plasmids containing ORFs 4 to 7 every 3 
weeks, 3 consecutive times. Cell-mediated immunity as measured by the number of PRRSV 
specific IFN-y producing cells and a lymphoproliferation assay was detected in all pigs 
immunized with DNA plasmids containing ORFs 4 to 7. However, PRRSV-specific 
neutralizing antibodies were only detected in pigs immunized with DNA plasmids containing 
either ORF 4 or 5. The results of this study suggest that the target of SN antibodies include 
epitopes of proteins encoded by ORFs 4 and 5 of PRRSV. 
Immunization with a plasmid DNA encoding the GP5 of PRRSV protected pigs from 
developing lung lesions and viremia following experimental challenge (Pirzadeh and Dea, 
1998). Immunized pigs also developed PRRSV specific SN antibodies. However, SN 
antibodies were not detected until 2 to 3 weeks after the second immunization. In contrast, 
immunization with the recombinant protein of GP5 expressed in E.coli did not induce an 
immune response. These observations confirm that the target of SN antibodies may include 
epitopes of proteins encoded by ORF 5 of PRRSV. However, the protein may require 
mammalian modification since the E.coli expressed ORF5 failed to elicit immune response. 
In addition to using molecular technologies to develop innovative PRRSV vaccines, 
cholera toxin (CT) has been investigated for its potential use as an adjuvant to enhance the 
efficacy of PRRSV (Foss et al., 2002). The use of CT is based on the finding from early 
studies that CT appears to have an immunostimulatory effect (Foss and Murtaugh, 1999a; 
Foss and Murtaugh, 2000). Giving CT at the time of PRRSV vaccination might induce a 
more robust immune response. In the study, pigs were injected with CT within a week of the 
administration of a commercial PRRSV MLV (Foss et al., 2002). Antibody responses were 
measured by commercial ELISA and anti-ORF5 ELISA assay. It was demonstrated that pigs 
receiving MLV in conjunction with CT had a more robust antibody response as measured by 
anti-ORF5 ELISA than pigs administered with MLV only. An increased antibody response 
was not observed by a commercial ELISA. ORF5 encodes glycoprotein 5, which is 
associated with the production of neutralizing antibodies. The increased level of antibody 
against GP5 suggested that CT might enhance the vaccine efficacy. 
Since antigenic diversity has been observed between PRRSV isolates, a vaccine based 
on a single strain may not be effective against antigenically distinct PRRSV isolates (Meng, 
2000). The effectiveness of a PRRSV vaccine may vary depending on the antigenic 
relatedness of the isolates to which pigs are exposed. Therefore, it was hypothesized that an 
attenuated multivalent vaccine comprised of multiple antigenically distinct strains of PRRSV 
would be more effective than a single strain vaccine. However, recent studies showed no 
evidence that either single-strain or multiple-strain vaccination provided a better level of 
immunity suggesting the hypothesis is not true (Mengeling et al., 2003a; Mengeling et al., 
2003b). Furthermore, recombination of strains contained in the multiple-strain MLV vaccine 
was reported (Mengeling et al., 2000), which may pose an increased risk to herd health. 
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CHAPTER 2. RESPONSES OF PIGS FOLLOWING VACCINATION WITH A 
COMMERCIAL KILLED PORCINE REPRODUCTIVE AND RESPIRATORY 
SYNDROME VIRUS (PRRSV) VACCINE CONTAINING INTERLEUKIN-12 AND A 
COMBINATION VACCINATION WITH MODIFIED-LIVE AND KILLED PRRSV 
VACCINES 
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ABSTRACT 
The objectives of this study were to determine if the addition of interleukin-12 (IL-
12) to a killed porcine reproductive and respiratory syndrome virus (PRRSV) vaccine (KV) 
would enhance the immune response to the KV and to investigate if a modified live PRRSV 
vaccine (MLV) followed by KV would result in a stronger immune response compared with 
either vaccine alone. Fifty, 3 to 4-week-old pigs were assigned to 6 treatment groups 
consisting of saline, IL-12, KV, KV+1L-12, MLV and MLV+KV. All pigs were challenged 
with the PRRSV isolate, VR-2402, at 43 days post vaccination (DPV) and euthanized 23 
days later. Only pigs vaccinated with the MLV, with or without KV, had increased antibody 
responses as measured by ELISA and serum neutralizing (SN) antibody assays following 
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vaccination. On 42 DPV, the pigs vaccinated with MLV+KV had higher SN antibody titers 
than pigs receiving MLV, although the difference was not statistically significant. 
Proliferation of T-cells increased in all vaccinated groups with an increased tendency for 
greatest proliferation in the MLV+KV group. All pigs displayed mild clinical respiratory 
disease following challenge. There was a significant reduction in clinical respiratory disease 
associated with KV+IL-12, but the magnitude or duration of viremia was not reduced. In 
contrast, combined MLV+KV reduced the level of clinical respiratory disease and the level 
of viral RNA in the serum. None of vaccination protocols reduced the amount of viral RNA 
in tonsil scrapings or bronchoalveolar lavage. The results of this study indicate that the 
addition of IL-12 to KV did little to enhance vaccine efficacy. Enhancement of SN antibody 
as well as reduction of respiratory signs in the MLV+KV group suggest the need for further 
investigation of this regimen for developing more effective vaccination strategies. 
Keywords: PRRSV, interleukin (IL)-12, modified-live virus vaccine, killed virus vaccine 
1. INTRODUCTION 
Porcine reproductive and respiratory syndrome virus (PRRSV) is a positive sense 
single-stranded RNA virus in the family Arteriviridae. Since its first emergence as a new 
swine disease entity in the late 1980's, PRRSV has continued to cause significant economic 
losses to the swine industry worldwide. Maintaining sufficient herd immunity in a sow herd 
appears to reduce clinical reproductive disease and allows for the production of weaned pigs 
free of PRRSV. 
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Regardless of the type of vaccine, there is considerable controversy over PRRSV 
vaccine efficacy. Current commercial PRRSV vaccines appear to provide a low level of 
effective immunity based on serum neutralizing (SN) antibody levels and cell-mediated 
immune (CMI) responses (Meier et al., 2003; Osorio et al., 1998). Modified-live PRRSV 
vaccines (MLV) were unable to stimulate either a strong CMI or a significant SN antibody 
titer following vaccination and an effective immune response did not become detectable until 
4-6 weeks post vaccination (Meier et al., 2003). Moreover, pigs vaccinated with the PRRSV 
MLV have the potential to spread the vaccine virus to non-vaccinated pigs (Christopher-
Hennings et al., 1997). Outbreaks of PRRSV in Denmark were attributed to the spread of 
PRRSV MLV virus from vaccinated boars in studs to susceptible pigs by either direct 
exposure or in semen (Botner et al., 1997). The efficacy of killed PRRSV vaccines (KV) is 
also questionable as they appear to induce poor antibody responses in PRRSV negative pigs 
(Osorio et al., 1998). However, there are several reports of enhanced SN antibody responses 
by KV when used in pigs previously infected with PRRSV and/or vaccinated with an MLV 
vaccine (Baker et al., 1999; Nilubol et al., 2004). In addition, the use of KV in pigs receiving 
multiple MLV vaccines stimulated increased antigen-specific T cell proliferation 
(Bassaganya-Riera et al., 2004). These observations suggest that the combination of MLV 
and KV vaccination may be more effective than either vaccine alone. 
Cytokines such as interleukin (IL) -12 have been used as adjuvants to enhance 
vaccine-induced immune responses (Afonso et al., 1994; Buchanan et al., 2001; Kincy-Cain 
et al., 1996). Interleukin-12 is a heterodimeric cytokine consisting of 35 and 40 kDa proteins 
secreted by monocytes, macrophages, and dendritic cells. It acts directly on CD4+ T-
lymphocytes to inhibit the production of IL-4 resulting in the differentiation of 
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undifferentiated T helper (Th) 0 cells to Th 1 cells following exposure to antigen (Seder et 
al., 1993). Production of Th 1 cells is important for eliminating virus-infected cells and 
clearing the virus from the infected animals. In addition, IL-12 enhances the cytolytic activity 
of NK cells and promotes interferon-gamma (IFN-y) production (Seder et al., 1993; 
Trinchieri and Scott, 1995), which has been reported to inhibit PRRSV replication (Rowland 
et al., 2001). With these potent immunoregulatory properties, IL-12 has been investigated as 
an adjuvant to enhance the efficacy of vaccines against pathogens in human, mice and pigs 
(Afonso et al., 1994; Buchanan et al., 2001; Kincy-Cain et al., 1996; Zuckermann et al., 
1998). 
This study investigated whether the addition of IL-12 to a commercially available 
PRRSV KV would enhance the immune response induced by the KV alone. Furthermore, the 
administration of MLV followed by KV was assessed to determine if this vaccination 
strategy would enhance the immune response compared to either vaccine alone. 
2. MATERIALS AND METHODS 
2.1. PRRSV Vaccines, virus and IL-12 
Vaccines used in this study were MLV (RespPRRS/Repro®, Boehringer Ingelheim 
Vetmedica Inc., St. Joseph, MO) and KV (PRRomiSe™, Intervet Inc., Millsboro, DE) 
vaccines. The MLV was developed from the North American prototype PRRSV isolate, VR-
2332, by serial attenuation in cell culture. The KV was developed from PRRSV isolate VR-
2402. Dosage and route of administration of the vaccines was according to each 
manufacturer's directions. 
The challenge virus used in the study was PRRSV isolate VR-2402. The seed virus 
was provided by Dr. Richard Hesse (Intervet Inc., Dallas Center, IA). The same virus was 
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also used for preparing the viral antigen for lymphocyte proliferation assays. The virus was 
propagated as previously described (Nilubol et al., 2004). The virus was harvested by a cycle 
of freezing/ thawing at -70 C / 37 C followed by centrifugation for 10 minutes at 1500 xg. 
The supernatant containing the viruses was inactivated with UV at 50,000 ja,Joules in a 
StrataLinker® UV Crosslinker (StrataGene, La Jolla, CA) prior to use in lymphocyte assays 
Porcine IL-12 (R&D Systems, Minneapolis, MN) is a recombinant disulfide-linked 
heterodimeric porcine protein consisting of both the p40 and p35 subunits. The proteins were 
provided in lyophilized form and reconstituted to 25 ja,g/ml in sterile PBS containing 0.2 % 
bovine serum albumin according to manufacturer's directions prior to use. 
2.2. IL-12 dose determination 
A preliminary study was conducted to determine the quantity of IL-12 required to 
enhance a KV-induced immune response. Pigs were vaccinated with KV containing different 
concentrations of IL-12. For this study, 16 two-week-old pigs obtained from a herd free of 
PRRSV were randomly assigned to 4 treatment groups, 4 pigs per group. Pigs in the KV 
control, group A, were vaccinated intramuscularly on days 0 and 14 with KV only. Groups 
B, C, and D were vaccinated intramuscularly on days 0 and 14 with KV containing 0.5, 3, 
and 5 (o.g of IL-12, respectively. Blood samples were collected on 0, 14, 28, and 42 day post 
vaccination (DPV). Antibody responses were measured by ELISA and SN assays. 
Enumeration of IFN-y staining cells in PBMCs was measured by intracellular flow 
cytometric assay. 
2.3. Experimental design 
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All study procedures and animal care activities were conducted in accordance with 
the guideline and approval of the Iowa State University Institutional Committee on Animal 
Care and Use. 
Fifty, 3 to 4-week-old crossbred pigs were obtained from a herd negative for PRRSV. 
Upon arrival, pigs were randomly allocated into 6 treatment groups with stratification by 
weight. Group 1 (n=5) was injected intramuscularly with 2 ml of sterile saline on 0 DPV. 
Group 2 (n=5) was injected intramuscularly with 5 jag IL-12 on 0 DPV. Group 3 (n=ll) was 
vaccinated with KV on 0 and 14 DPV. Group 4 (n=l 1) was vaccinated intramuscularly with 
KV containing 5 p,g of IL-12 on 0 and 14 DPV. Group 5 (n=10) was vaccinated with MLV 
on 0 DPV. Group 6 (n=10) was vaccinated with MLV on 0 DPV followed by KV on 14 and 
28 DPV. All groups were challenged intranasally with 2 ml of PRRSV isolate VR-2402 (104 
TCLDso/ml, 1 ml per nostril) on 43 DPV to evaluate protective immunity. 
Blood samples were collected from all pigs on 0, 28, 42, 50 (7 days post infection, 
DPI), 57 (14 DPI) and 66 (23 DPI) DPV and assayed for virus, viral RNA, PRRSV specific 
antibodies and T cell proliferation to antigens. Oropharyngeal scraping samples were 
collected on 50 (7 DPI) and 66 (23 DPI) DPV and assayed for virus and viral RNA. 
Bronchiole alveolar lavage samples were collected at necropsy on 66 (23 DPI) DPV. 
2.4 Clinical evaluation 
All pigs were evaluated for clinical respiratory signs and rectal temperatures daily for 
9 days following challenge. A clinical respiratory disease score was given to each pig as 
previously described (Halbur et al., 1995). Pigs with rectal temperatures > 40 C were 
classified as febrile and the number of febrile days for each pig was calculated. 
2.5 Blood collection 
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Blood was collected in serum tubes (SST Vacutainer™, Becton Dickinson, Franklin 
Lakes, NY) and sterile heparinized tubes (BD Vacutainer™ Sodium Heparin, Becton 
Dickinson, Franklin Lakes, NY). Sera were stored at -80°C until assayed. Whole blood in 
sterile heparinized tubes was used for lymphocyte isolation to measure CMI responses. 
2.6 Antibody response 
2.6.1 Enzyme linked immunosorbent assay 
Sera were assayed for PRRSV specific antibodies using a commercial ELISA 
(IDEXX Laboratories, Westbrook, ME) according to the manufacturer's instructions. The 
presence or absence of antibodies was determined by calculating the sample-to-positive (S/P) 
ratio. A sample was considered to be positive for PRRSV antibody if the S/P ratio was > 0.4. 
2.6.2 Serum neutralizing antibody assay 
Serum samples were heat-treated at 56 C for 30 minutes and diluted two-fold in 
DMEM supplemented with 3% fetal bovine serum (FBS) and 50 p.g/ml gentamicin. Each 
dilution of serum was mixed with an equal volume of PRRSV diluted to contain 103 
TCrD50/ml. Serum/virus mixtures were incubated for 60 minutes at 37 C in a 5% carbon 
dioxide, humidified atmosphere. Two hundred p,L of each serum/virus mixture were added in 
duplicate to wells of a 96-well microliter plate containing 48-hour-old confluent MARC-145 
cell monolayers and incubated for 2 days at 37 C in a 5% CO2, humidified atmosphere. Cell 
monolayers were fixed with a cold acetone-methanol solution, stained with FITC-conjugated 
monoclonal antibodies against nucleoprotein of PRRSV (SDOW-17, Rural Technologies, 
Inc., Brooking, SD) and visualized with fluorescence microscopy. 
2.7 Cell-mediated Immunity (CMI) 
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2.7.1 Harvesting of peripheral blood mononuclear cells 
PBMCs were isolated from whole blood as previously described (Waters et al., 1999). 
PBMCs were resuspended in 1 ml RPMI 1640 media supplemented with 10% FBS, 2 mM L-
glutamine, and 50 ng/ml gentamicin (complete media). 
2.7.2 PKH67 proliferation assay 
The lymphocyte proliferation assay coupled with the expression of cell surface 
markers was performed as previously described (Waters et al., 1999) with the exception that 
the green fluorescent dye PKH67 (Sigma, St. Louis, MO) was used instead of PKH2. Briefly, 
2xl07 PBMCs were resuspended in 1 ml of diluent C containing 2 p,l of PKH67 per 1 ml and 
incubated at room temperature for 5 minutes followed by 1 minute with 2 ml of FBS to stop 
the reaction. PBMCs were then washed three times and adjusted to 5xl06 cells in 1 ml of 
complete media. One hundred jul of cells were added to 96-well round-bottomed microliter 
plates containing media alone (negative stimulation), PHA (5 (ig/ml, positive stimulation) or 
UV-inactivated PRRSV VR-2402 antigen (Multiplicity of infection, MOI, of 1) and 
incubated at 37 C in a 5% CO2, humidified atmosphere for 5 days. 
After a 5-day incubation, the labeled cells were stained with primary antibody to 
swine leukocyte surface antigens including PE-conjugated anti-porcine CD4 (clone 74-12-4, 
BD Biosciences, San Diego, CA) and biotinylated anti-porcine CDS (clone 76-2-11, kindly 
provided by Dr. M.J. Wannemuehler, Iowa State University, Ames, IA, USA) as previously 
described (Waters et al., 1999). Then cells were incubated with streptavidin-CyChrome 
(CyChrome, BD Biosciences, San Diego, CA) for biotinylated anti-porcine CDS. 
Proliferation and lymphocyte populations were determined by flow cytometric analysis 
detecting 10,000 events per sample (FACScan, Becton-Dickinson, Mountain View, CA). 
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Flow cytometric data was analyzed using a proliferation wizard module, ModFit software 
(Verity Software House, Topsham, ME) as previously described (Givan et al., 1999). 
Proliferation of each T-lymphocyte subset was reported as a proliferation index, which is the 
sum of the cells in all generations divided by the computed number of original cells 
theoretically present at day 0 (before incubating PBMC with antigen). 
2.7.3 Intracellular IFN-y flow cytometric assay. 
The assay was conducted as previously described (Foster and Prussin, 2002) with 
minor modifications. In brief, 5xl06 PBMCs were suspended in 1 ml of complete media. One 
hundred ju.1 of cells were added to 96-well round-bottomed microtiter plates containing 100 
(j.1 of media alone (negative stimulation), media plus PHA (0.5 jig/ml, positive stimulation) 
or media plus a UV-inactivated PRRSV VR-2402 antigen (MOI of 1) and incubated at 37 C 
in a 5% CO2 humidified atmosphere for 5 days. PBMCs were re-stimulated with 100 p.1 of a 
complete media containing 20 ng/ml of phorbol myristate acetate, 1 jag of ionomycin, and 10 
(j,g of Brefeldin 4 hours prior to conducting the assay. All wells were fixed and permeabilized 
in Cytofix/Cytoperm solution (BD Biosciences, San Diego, CA) for 20 minutes at 4 C, 
washed and then incubated for 20 minutes at 4 C with PE-conjugated antiporcine IFN-y or an 
specific isotype (BD Biosciences, San Diego, CA) in Perm/Wash solution provided with 
Cytofix/Cytoperm solution. PBMCs were washed, reconstituted in 200 fil of Perm/Wash 
solution and analyzed by flow cytometry at 20,000 events per sample. 
2.8 Virus isolation 
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Tonsil scraping and BAL samples were assayed for virus by inoculation in duplicate 
using 200 jj,1 of filtered sample onto 48-hour-old confluent MARC-145 cell monolayers 
contained in 48-well tissue culture plates as previously described (Horter et al., 2002). 
2.9 Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) 
2.9.1 Nested RT-PCR (NRT-PCR) 
Analysis of tonsil scrapings and BAL samples for viral RNA was conducted using a 
NRT-PCR protocol for the ORF 7 region of PRRSV previously described (Christopher-
Hennings et al., 1995). 
2.9.1 Quantitative real time RT-PCR (QRT-PCR) 
Analysis of serum for viral RNA quantification was conducted using the QRT-PCR 
protocol previously described (Vincent et al., 2004). In brief, one-tube RT-PCR was 
performed in duplicate for each test serum sample using the Brilliant® single-step QRT-PCR 
system (Stratagene, La Jolla, CA). The reactions were carried out in a Rotor-Gene 4.6 real 
time thermal cycler system (Corbett Research, Mortlake, NSW, Australia). The calculated 
concentrations for the two replicates were averaged to give the copy number per /zl of the 
ORF 7 transcript in the sample when the difference between the two samples was less than 
one log unit. If the difference exceeded this limit, the results were considered questionable 
and the sample was re-tested. 
2.10 Statistical analysis 
Percentages of IFN-y staining cells, lymphocyte proliferation indices and logarithmic 
transformation of viral RNA level in serum were analyzed by analysis of variance (ANOVA) 
to determine if there were significant differences between the treatment groups. If the />value 
for an ANOVA table was less than 0.05, the differences between treatment groups were 
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evaluated by pairwise comparisons at the p<0.05 rejection level. Respiratory clinical scores 
were analyzed by the Kruskal-Wallis ANOVA. The data from repeated measurements of 
antibody responses was analyzed by using multivariate ANOVA. 
3. RESULTS 
3.1. Dosage determination of IL-12 
All pigs responded serologically to KV vaccination, with or without IL-12, however, 
all ELISA titers remained lower than 0.4, the positive cut-off suggested by manufacturer 
(data not shown). The mean ELISA titers of pigs vaccinated using KV with IL-12 added 
were higher than those of pigs vaccinated with KV alone on 28 and 42 DPV. Groups 
receiving KV with 3 and 0.5 (j,g of IL-12 added displayed the highest and lowest responses, 
respectively. No statistical difference between groups or a linear correlation between the 
concentration of IL-12 and ELISA titers was demonstrated. No SN antibodies were detected 
in any pigs from any treatment group. 
Regardless of treatment, the mean percentage of PRRSV specific CD8+ lymphocytes 
increased following vaccination, reaching the highest level at 28 DPV and then decreased 
between days 28 to 42 (data not shown). In contrast, the mean percentage of PRRSV-specific 
CD4+ T-lymphocytes decreased throughout the experiment. The mean percentage of 
CD8+CD4+ double positive (DP) T-lymphocytes decreased during the first two weeks and 
increased thereafter. However, no significant differences between treatment groups in 
percentages of CD8+, CD4+ and CD8+CD4+ DP T-lymphocytes were observed at any time. 
The addition of IL-12 to KV resulted in significantly increased number of IFN-y staining 
cells compared to KV alone on day 14 and the response was not dose dependent (Figure 1). 
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Figure 1. The mean percentage of interferon-gamma staining cells in peripheral blood mononuclear cells of pigs vaccinated 
with a killed PRRSV vaccine (KV) containing 0, 0.5, 3, or 5 jag of interleukin-12. Responses were expressed as mean 
percentages of interferon-gamma staining cells + one standard deviation. 
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3.2 Antibody responses 
3.2.1 ELISA 
Following vaccination, all pigs vaccinated with MLV, either alone or followed by 
KV, seroconverted to PRRSV on 28 DPV (data not shown). All non-vaccinated pigs 
remained seronegative until challenged. Addition of IL-12 to the KV resulted in slightly 
increased ELISA titers compared to KV alone on 28 and 42 DPV; however, the ELISA titers 
were lower than the positive/negative cut-off. Only 1 pig in the KV+IL-12 group had the 
ELISA titer more than 0.4 on 28 and 42 DPV. Following challenge, only control and pigs 
vaccinated with KV, with or without IL-12, had increased antibody levels. While four of 11 
pigs in the KV only groups had the ELISA titer less than 0.4 on 7 DPI, only two of 11 pigs in 
the KV+IL-12 group had the ELISA titer less than 0.4. All pigs vaccinated with KV, with or 
without IL-12, had the ELISA titer more than 0.4 (the positive/negative cut-off) on 14 DPI. 
Following challenge, the ELISA titers increased more rapidly in KV-vaccinated pigs, either 
with or without IL-12, than non-vaccinated pigs. While groups vaccinated with MLV, either 
alone or followed by KV, remained at levels similar to pre-challenge. 
3.2.2 SN antibody response 
Following vaccination, only pigs vaccinated with MLV, either alone or followed by 
KV, were positive for SN antibodies against both PRRSV isolates on 42 DPV (Figures 2 and 
3). While eight of ten pigs in the MLV+KV group had the detectable level of SN antibodies, 
only four of ten pigs in the MLV only group had the detectable SN antibodies. Vaccination 
with MLV followed by KV resulted in higher levels of SN antibodies against both PRRSV 
isolates compared to either vaccine alone on 42 DPV ; however, the difference was not 
statistically significant. The SN antibodies against both PRRSV isolates increased following 
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Figure 2. Serum neutralizing antibody response of pigs vaccinated with 5 (j.g interleukin (IL)-12, saline, killed PRRSV vaccine 
(KV) with and without 5 jj.g IL-12, a modified live PRRSV vaccine (MLV) or MLV followed by KV. The assay was conducted 
using PRRSV isolate VR-2402 as antigen. All groups were challenged with PRRSV isolate VR-2402 on day 43 post vaccination 
(arrow). Responses were expressed as arithmetic means + one standard deviation. 
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Figure 3. Serum neutralizing antibody response of pigs vaccinated with 5 ^g interleukin (IL)-12, saline, killed PRRSV 
vaccine (KV) with and without 5 (j.g IL-12, a modified live PRRSV vaccine (MLV) or MLV followed by KV. The assay 
was conducted using PRRSV isolate VR-2332 as antigen. All groups were challenged with PRRSV isolate VR-2332 on 
day 42 post vaccination (arrow). Responses were expressed as an arithmetic mean + one standard deviation. 
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challenge. No SN antibodies were detected in pigs vaccinated with KV, either with or 
without IL-12, until 57 DPV (14 DPI) and the levels of SN antibodies against PRRSV VR-
2402 were greater than that against PRRSV VR-2332. While six of nine pigs in the KV+IL-
12 group had the detectable SN antibodies, only three of nine pigs in the KV only group had 
the detectable SN antibodies. SN antibodies were first detected in seven of eight control pigs 
on 23 DPI. 
3.3 PKH67 proliferative response 
Proliferation of PRRSV specific CD4+, CD8+ and CD4+CD8+ T-lymphocytes 
increased following vaccination in all groups with an increased tendency in the group 
vaccinated with both the MLV and KV. The magnitude of CD4+CD8+ lymphocytes 
proliferation response was higher in vaccinated groups than non-vaccinated groups on 28 
DPV; however, no statistical difference was detected. The proliferation responses of CD4+ 
and CD8+ lymphocytes were similar in all vaccinated groups. 
Following challenge on 43 DPV, the proliferation response of CD4+ T-lymphocytes 
increased in all groups. The response was transient with the greatest proliferation occurring at 
50 DPV followed by a decrease in the proliferation index. The proliferation response of 
CD8+ T-lymphocytes also increased over time in all treatment groups. On 57 DPV, all 
vaccinated groups had significantly higher CD8+ T-lymphocytes proliferation response than 
the non-vaccinated group. The group vaccinated with the MLV and KV had significantly 
increased CD8+ lymphocyte proliferation response compared to the groups vaccinated with 
either vaccine alone. There was no apparent increase in proliferation response of CD4+CD8+ 
T-lymphocytes, although the overall proliferation index of all groups increased over time. 
3.4 Evaluation of protection against challenge 
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3.4.1 Clinical evaluation 
All groups inoculated with PRRSV displayed clinical symptoms of respiratory 
disease consistent with PRRSV pneumonia (Table 1). Clinical respiratory signs included 
labored and abdominal breathing. Control groups receiving saline or IL-12 displayed the 
most severe clinical disease. Pigs vaccinated with either MLV or KV had significantly less 
clinical disease compared to the control pigs. Pigs vaccinated with the KV with IL-12 had the 
greatest reduction in clinical disease compared to control. Administration of MLV followed 
by KV also reduced clinical disease; however, the difference was not statistically significant 
compared to either vaccine alone. There was no difference between treatment groups in the 
number of days that pigs had rectal temperatures > 40 C. 
3.4.2 Virus detection in serum, tonsil scrapings and BAL 
Following challenge, administration of MLV, either alone or followed by KV, 
reduced the magnitude and duration of viremia as measured by QRT-PCR (Table 2). While 
no pigs in the MLV+KV group were PCR positive, one pig vaccinated with the MLV was 
PCR positive on 50 DPV. No reduction in viral level or duration of viremia was observed in 
any pigs vaccinated with KV only or KV+IL-12 compared to controls. In contrast to PRRSV 
levels in the serum, the administration of MLV, either alone or followed by KV, did not 
result in elimination of viral RNA in tonsil scrapings and BAL samples. Regardless of 
treatment, viral RNA was consistently detected in tonsil scrapings and BAL samples by 
NRT-PCR in the majority of pigs (Table 3). 
4. DISCUSSION 
Several previous studies reported that the development of an effective immune 
response including SN antibodies and T lymphocyte responses are relatively delayed 
52 
Table 1. 
Summary of average clinical respiratory scores and fever 0-9 days after challenge with 
PRRSV. 
Treatments* Respiratory score** No. of febrile*** 
IL-12 6.4+ 1.34* 0.8 ±0.84 
Saline 5.8 + 1.30' 1.4 ± 1.67 
KV 4+ 1.34^ 1.64 ± 1.36 
KV + IL-12 1.73 ±1.34" 1.36 ± 1.80 
MLV 3.7 ± 1.77^ 0.6 ±0.84 
MLV + KV 2.7 + 1.77b'c 0.3 + 0.95 
* Pigs were injected with 5 p.g interleukin (IL)-12, saline, killed PRRSV vaccine (KV) with 
and without 5 |ig IL-12, a modified live PRRSV vaccine (MLV) or MLV followed by KV. 
** Respiratory score: 0 = normal; 1 = mild dyspnea and/ or tachypnea when stressed; 2 = 
mild dyspnea and/ or tachypnea when at rest; 3 = moderate dyspnea and/ or tachypnea when 
stressed; 4 = moderate dyspnea and/ or tachypnea when at rest; 5 = severe dyspnea and/ or 
tachypnea when stressed; 6 = severe dyspnea and/ or tachypnea when at rest. Scores are 
displayed as a mean + one standard deviation. 
*** Pigs with > 40 C rectal temperature were considered to be febrile. 
a
'
b
'
c Means with different superscripts within a column are statistically different (p<0.05) 
following PRRSV infection or vaccination with either MLV or KV (Meier et al., 2003; 
Osorio et al., 1998). The objective of this study was to determine if the addition of IL-12 to a 
commercial adjuvanted PRRSV KV would enhance the immune response to the KV. 
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Table 2. 
Viral RNA levels in serum following challenge as measured by quantitative real-time RT-
PCR. Results are displayed as copies per ml. 
Days after vaccination 
Treatments* 50 57 66 
IL-12 6.64x10*' (5/5)** L50xlCf' (3/3) 1.92x10*» (2/3) 
Saline 4.97x10*» (5/5) 2.65x10*» (5/5) 3.18x10)4» (2/5) 
KV 4.17x10*' (7/10) 4.95x10^» (4/9) 3.73x10*' (2/9) 
KV + IL-12 6.51x10^» (7/11) 3.87x10^» (4/9) 4.16x10*» (1/9) 
MLV 1.04xl04b (1/10) 0b (0/10) 0»(0/10) 
MLV + KV 0 f (0/10) 0\0/10) 0» (0/10) 
* Pigs vaccinated with 5 pg interleukin (IL)-12, saline, killed PRRSV vaccine (KV) with and 
without 5 |o.g IL-12, a modified live PRRSV vaccine (MLV) or MLV followed by KV. Pigs 
were challenged with PRRSV VR-2385 on 43 days post vaccination. 
** Number of PCR positive/ number tested 
a
'
b
'
c Means with different superscripts within a column are statistically different (p<0.05) 
Furthermore, a protocol in which a PRRSV MLV was used to prime the immune response 
and followed by boostering with PRRSV KV was also evaluated with regard to increasing 
the magnitude and fastening the onset of the immune response developed compared to either 
vaccine alone. 
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Table 3. 
Nested RT-PCR results in tonsil scraping and bronchoalveolar lavage samples following 
PRRSV challenge. 
Nested RT-PCR results following challenge 
Treatments* Tonsil 
DPI** 
scraping at 7 Tonsil scraping at 23 
dpi 
BAL at necropsy 
IL-12 4/4*** 2/2 2/2 
Saline 3/3 5/5 5/5 
KV 9/10 8/8 8/8 
KV + IL-12 8/9 8/8 8/8 
MLV 8/9 4/5 2/5 
MLV + KV 10/10 4/5 4/5 
* Pigs vaccinated with 5 jug interleukin (IL)-12, saline, killed PRRSV vaccine (KV) with and 
without 5 fj,g IL-12, a modified live PRRSV vaccine (MLV) or MLV followed by KV and 
challenge with PRRSV VR-2385 on 43 days post vaccination. 
** days post challenge 
*** Values are numbers of serum or tissues positive for PRRSV RNA was isolated relative 
to numbers tested by Nested RT-PCR. 
The results of this study demonstrated that the addition of IL-12 did little to enhance 
KV efficacy. The addition of IL-12 slightly enhanced the antibody response as measured by 
ELISA compared to the KV alone, but did not enhance the CMI response. Although the 
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administration of the KV with IL-12 significantly reduced clinical respiratory disease, 
viremia was not reduced. Previously, the use of IL-12 in conjunction with attenuated and 
inactivated PRRSV vaccines was demonstrated to enhance antibody and CMI responses to 
both vaccines (Foss et al., 2002; Wee et al., 2001). Vaccination with an inactivated PRRSV 
vaccine with added IL-12 resulted in a significant enhancement of antibody responses as 
measured by ELISA and CMI responses in similar magnitude to that induced by MLV 
vaccination (Wee et al., 2001). A robust response of IFN-y as measured by ELISPOT 
following immunization with an attenuated PRRSV vaccine in conjunction with IL-12 was 
also observed (Foss et al., 2002). The results of those studies contrast with our findings that 
IL-12 did not enhance the immune response to the KV. A potential explanation for the 
difference between studies is the difference in PRRSV isolates and the adjuvant used in the 
KV. In an earlier study, a field PRRSV isolate inactivated by binary ethylamine and absorbed 
onto Al(OH)3 was used to immunize pigs (Wee et al., 2001). In contrast, the KV used in the 
present study was a commercial KV manufactured from PRRSV isolate VR-2402 and 
formulated with a proprietary adjuvant. Further investigation is needed to determine if the 
ingredients used in the adjuvant in the commercial KV would alter the activity of IL-12. 
Furthermore, while the biological effects of IL-12 have been well studied in mice and 
humans, the biological activities of IL-12 in pigs are less defined. Research suggests that the 
biological effects of IL-12 in pigs may be inconsistent compared with the responses observed 
in mice and humans (Domeika et al., 2002; Solano-Aguilar et al., 2002). In vitro and in vivo 
experiments comparing the responsiveness of bovine and porcine lymphoblasts to IL-12 
demonstrated little change in the proliferation of porcine lymphoblasts as measured by [3H] 
thymidine incorporation compared to the proliferation of bovine lymphoblasts (Solano-
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Aguilar et al., 2002). A recent study also showed that the biological effects of IL-12 on 
porcine cells may be dependent on the presence of a co-stimulatory cytokine such as IL-18 
(Domeika et al., 2002). It would have been helpful in the present study to determine the 
efficacy of IL-12 in the induction of IFN-y. However, cells producing IFN-y in response to 
IL-12 were measured in the pilot study only. 
The administration of MLV followed by KV vaccination demonstrated a slight 
increase in the rate of development of SN antibodies, although the increased immune 
responses were not statistically significant. It is interesting to note that T lymphocyte 
responses following challenge were by CD4+ and CD8+ T-lymphocytes, not CD4+CD8+ DP 
T-lymphocytes. Further studies are needed to determine whether the response of CD4+ T-
lymphocytes is switched toward a Th 1 or Th 2 response. Proliferation of B-lymphocytes was 
not measured in this study. 
It is noteworthy that the pigs previously vaccinated with KV and then challenged with 
PRRSV responded immunologically to the homologous virus challenge more rapidly than 
pigs that were challenged with PRRSV only. SN antibody levels and CMI responses as 
measured by lymphocyte proliferation assays were observed as soon as 2 weeks following 
PRRSV challenge, in contrast to the 4-5 weeks previously described for infected pigs 
(Bautista and Molitor, 1997; Lopez Fuertes et al., 1999; Yoon et al., 1996). Further 
investigation is needed to determine if the use of KV followed by MLV vaccination could 
enhance protective immune responses compared to either vaccination alone. In the study 
reported here, KV vaccination alone did not induce a measurable antibody response as 
detected by either ELISA or SN antibody assay. However, a T-lymphocyte response as 
measured by lymphocyte proliferation was detected. These results are in agreement with an 
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earlier report that PRRSV KV vaccination can induce a CMI response (Bassaganya-Riera et 
al, 2004). 
All treatment groups displayed clinical respiratory disease following PRRSV 
challenge. Non-vaccinated control groups (saline or IL-12 alone) displayed the most severe 
clinical respiratory disease. The addition of IL-12 to KV and the combination vaccination 
protocol resulted in a significant reduction of clinical respiratory disease compared to 
vaccination with either vaccine alone. Although the pigs vaccinated with KV+IL-12 
exhibited the mildest clinical disease, no reduction in the magnitude and duration of viremia 
was demonstrated suggesting that clinical disease may not be correlated to virus level. A 
problem found with the PRRSV VR-2402 challenge was the relatively mild clinical 
respiratory disease induced by this isolate compared to other PRRSV isolates investigated in 
earlier studies (Halbur et al., 1995). This made comparison of clinical disease between 
groups problematic. 
Only MLV vaccination, with or without KV, reduced viremia following challenge. 
While viral RNA was detected in the serum of one pig in the MLV group at 50 DPV (7 DPI), 
all pigs were virus negative in the combination vaccination group. The MLV vaccinated pigs, 
with or without KV, had SN antibodies prior to challenge, while the KV, with or without IL-
12, and the control groups did not. This finding suggests that SN antibodies might confer 
protection resulting in the reduction of viremia. Further studies are needed for this 
vaccination strategy. It is noteworthy that although the MLV vaccination, with or without 
KV, reduced the magnitude and duration of viremia compared to vaccination with either 
vaccine alone, viral RNA was still detected in tonsil scrapings and BAL of all vaccinated 
pigs at necropsy. 
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In summary, the results of this study suggest that the use of IL-12 as an adjuvant did 
little to enhance the efficacy of PRRSV KV. The addition of IL-12 to a commercial PRRSV 
KV reduced clinical disease, but not viremia or viral persistence in tonsils or BAL. The use 
of KV in MLV vaccinated pigs slightly increased SN antibody levels and slightly reduced 
viremia and clinical respiratory disease, but had no impact on viral persistence. The MLV 
vaccination, with or without KV, reduced, but did not eliminate clinical disease and viremia 
but had limited impact on the persistence of virus at the primary infection site, the respiratory 
tract. These findings suggest the need for further investigation in order to enhance the 
immune responses elicited by commercial vaccines for controlling PRRSV. 
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CHAPTER 3. IMMUNE RESPONSES AND PROTECTION AGAINST HIGH AND 
LOW VIRULENT PRRSV IN PIGS VACCINATED WITH MODIFIED LIVE AND 
KILLED PRRSV VACCINE, EITHER ALONE OR IN COMBINATION 
A paper to be submitted to Vaccine 
D. Nilubol11, B.J. Thackerb, D.L. Harris*3 and E.L. Thacker3 
^Department of Veterinary Microbiology and Preventive Medicine and 
^Department of Veterinary Diagnostic and Production Animal Medicine, Iowa State 
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ABSTRACT 
The vaccine efficacy and level of immune response of pigs vaccinated with modified 
live (MLV) and killed (KV) porcine respiratory syndrome virus (PRRSV) vaccines, either 
alone or in combination, and subsequently challenge with high or low virulence PRRSV were 
investigated. Fifty-five, two-week old PRRSV negative pigs were assigned to 6 treatment 
groups consisting of non-challenged - no vaccination, challenged - no vaccination, KV, 
MLV, MLV followed by KV (MLV>KV), and KV followed by MLV (KV>MLV). Pigs 
were vaccinated with 1 dose of MLV and 2 doses of KV, either alone or in combination, 2 
weeks apart. At 44 days post vaccination (DPV), half of each group was challenged with a 
high virulence PRRSV isolate, VR-2385, and the other half was challenged with a low 
virulence PRRSV isolate, NADC-8. All pigs were necropsied at 54 DPV (10 days post 
infection). PRRSV-induced pneumonia was scored. The MLV>KV significantly enhanced 
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SN antibody levels and the proliferation of CD4+CD8+ T cells compared to either vaccine 
alone at 42 and 54 DPV, respectively. In addition, the administration of MLV, either alone or 
followed by KV, resulted in a significant reduction of viral RNA in serum and macroscopic 
lung lesions at necropsy compared to other treatments independent of which isolate was used 
for challenge. No enhanced SN antibodies, and reduced viremia and lung lesion were 
observed in the KV>MLV group. The results of this study demonstrated that a vaccination 
strategy consisting of MLV followed by KV induced a stronger immune response compared 
to vaccination with either vaccine alone. 
Keywords: low virulence, high virulence, PRRSV, modified-live virus vaccine, killed virus 
vaccine 
1. INTRODUCTION 
Porcine reproductive and respiratory syndrome virus (PRRSV), a positive sense 
single-stranded RNA virus, belongs to the family Arteriviridae. The virus is the etiologic 
agent of a syndrome characterized by reproductive and respiratory disorders in pigs and has a 
significant economic impact on swine production worldwide. 
Vaccination has been used as a tool to enhance the immune status of a herd and to 
prevent clinical disease and reduce or eliminate virus shedding. Several studies have 
evaluated the humoral (HI) and cell-mediated immune (CMI) responses induced by modified 
live (MLV) and killed (KV) PRRSV vaccines. Previous studies demonstrated that current 
PRRSV vaccines provide a low level of effective immunity based on serum neutralizing (SN) 
antibody levels and CMI responses (Osorio et al., 1998; Meier et al., 2003). Modified-live 
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PRRSV vaccines were unable to stimulate either a strong CMI or a significant SN antibody 
titer immediately following vaccination. An effective immune response including SN 
antibodies and the production of IFN-y secreting cells did not become detectable until 4-6 
weeks post vaccination (Meier et al., 2003). In addition, pigs vaccinated with the PRRSV 
MLV have the potential to spread the vaccine virus to non-vaccinated pigs (Christopher-
Hennings et al., 1997). 
Little is known about PRRSV KV vaccines. While KV do not induce detectable 
levels of antibodies in PRRSV naïve pigs (Osorio et al., 1998), a low level of CMI response 
has been detected (Bassaganya-Riera et al., 2004). While, the administration of KV to naïve 
pigs did not result in an antibody response, there have been several reports of enhanced SN 
antibody and CMI responses by KV when used in pigs previously exposed to PRRSV, either 
by field infection and/or MLV vaccination (Baker et al., 1999; Nilubol et al., 2004; 
Bassaganya-Riera et al., 2004). In addition, a study conducted in our laboratory demonstrated 
that pigs previously vaccinated with KV responded to experimental challenge more rapidly 
than naïve pigs as measured by ELISA and SN antibodies. These observations suggest that 
the combination of MLV and KV vaccination protocols may be effective strategies for 
controlling PRRSV in infected herds. 
The objective of this study was to characterize both the humoral and CMI responses 
induced by vaccination with MLV and KV PRRSV vaccines, either alone or in combination. 
The parameters evaluated included antibody responses as measured by ELISA and SN assays 
and lymphocyte proliferation assays to assess CMI responses. In addition the level of 
protection against disease was evaluated based on the severity of clinical disease and viremia 
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as measured by real time quantitative RT-PCR following challenge with high and low 
virulent PRRSV isolates. 
2. MATERIALS AND METHODS 
2.1. PRRSV vaccines and viruses 
Vaccines used in this study were MLV (RespPRRS/Repro®, Boehringer Ingelheim 
Vetmedica Inc., St. Joseph, MO) and KV (PRRomiSe™, Intervet Inc., Millsboro, DE) 
vaccines. The MLV was developed from the North American prototype PRRSV isolate, VR-
2332, by serial attenuation in cell culture. The KV was developed from PRRSV isolate VR-
2402. Dosage and route of administration of the vaccines was according to each 
manufacturer's directions. 
Four PRRSV isolates, VR-2332, VR-2402, VR-2385 and NADC-8 (kindly provided 
by Dr. Kelly Lager, National Animal Disease Center, Ames, IA) were used in this study. VR-
2332 and VR-2402, the viruses in MLV and KV, respectively were used in ex vivo cell 
culture studies to measure the proliferative responses of T and B lymphocytes to antigen. 
VR-2385 and NADC-8 were used to challenge pigs to measure protective immunity. VR-
2385 is a moderate-to-high virulent PRRSV isolate, and the virulence and pathogenicity have 
been well characterized (Halbur et al., 1995; Halbur et al., 1996). NADC-8 is a low virulent 
PRRSV isolate (Lager et al., 1999). The viruses were propagated in MARC-145 cells as 
previously described (Nilubol et al., 2004). The virus was harvested by a cycle of freezing/ 
thawing at -70 C/37 C followed by centrifugation for 10 minutes at 1500 xg. The supernatant 
which contained the virus was used to challenge pigs. For ex vivo cell culture studies, the 
supernatant was inactivated by exposure to UV at 50,000 |aJoules in a StrataLinker® UV 
Crosslinker (StrataGene, La Jolla, CA) prior to use in lymphocyte assays. 
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2.2. Experimental design 
All study procedures and animal care activities were conducted in accordance with 
the guideline and approval of the Iowa State University Institutional Committee on Animal 
Care and Use. 
Fifty-five, two-week-old crossbred pigs were procured from a herd free of PRRSV. 
Upon arrival, pigs were assigned randomly to the following treatment groups (Table 1); 1) 
negative control- no vaccination or challenge (n=5); 2) challenge control- no vaccination, but 
challenged (n=10); 3) KV vaccination only (n=10); 4) MLV vaccination only (n=10); 5) 
MLV followed by KV (MLV>KV, n=10); 6) KV followed by MLV (KV>MLV, n=10). The 
KV group was vaccinated with 2 doses of KV at 0 and 14 days post vaccination (DPV). The 
MLV group was vaccinated with one dose of MLV at 0 DPV. The MLV+KV group was 
vaccinated with one dose of MLV at 0 DPV followed by 2 doses of KV at 14 and 28 DPV. 
The KV>MLV group was vaccinated with KV at 0 and 14 DPV, followed by MLV at 28 
DPV. Dose and administration route of vaccination were used according to each 
manufacturers' directions. 
All pigs except group 1 pigs were challenged with PRRSV at 44 DPV. Half of each 
vaccination group was challenged with 2 ml of a moderate-to-highly virulent PRRSV isolate 
VR-2385 (104 75 TCIDso/ml, 1 ml per nostril) and the other half was challenged with a low 
virulent PRRSV virus isolate NADC-8 (105 TCID^/ml, 1 ml per nostril). Following 
challenge, pigs were evaluated daily for fever and clinical signs consistent with PRRSV 
infection. All pigs were necropsied at 54 DPV (10 days post challenge). Lung lesions were 
scored according to the severity of PRRSV-induced pneumonia. Serum and whole blood 
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were obtained at 0, 28, 42 DPV and at necropsy (54 DPV) for evaluating serum antibody 
responses, CMI responses, and serum viral RNA concentrations. 
Table 1. 
Experimental design for a study in which pigs were vaccinated with modified live and killed 
PRRSV vaccines, either alone or in combination, followed by challenge with a low (NADC-
8) or high (VR-2385) virulent PRRSV isolate at 44 days post vaccination 
Treatments Descriptions Challenge 
Negative control (n=5) Non-challenge control No 
Challenge control (n=10) Challenge control VR-2385 (n=5 or 
NADC-8 (n=5 
KVa (n=10) KV at 0 and 14 DPVe VR-2385 (n=5 or 
NADC-8 (n=5 
MLVb (n=10) MLV at 0 DPV VR-2385 (n=5 or 
NADC-8 (n=5 
MLV>KV (n=10) MLV at 0 DPV and KV VR-2385 (n=5 or 
at 14 and 28 DPV NADC-8 (n=5 
KV>MLV (n=10) KV at 0 and 14 DPV VR-2385 (n=5 or 
and MLV at 28 DPV NADC-8 (n=5 
a Killed PRRSV vaccine 
b Modified live PRRSV vaccine 
c Days post vaccination 
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2.3. Antibody response 
PRRSV-specific antibodies were measured by ELIS A and SN antibody assays. A 
commercial ELIS A kit (IDEXX Laboratories, Westbrook, ME) was used according to the 
manufacturer's instructions. The presence or absence of antibody was determined by 
calculating the sample-to-positive (S/P) ratio. A sample was considered to be positive for 
PRRSV antibody if the S/P ratio was > 0.4. A SN antibody assay was performed as 
previously described (Nilubol et al., 2004) 
2.4. Cell-mediated Immunity (CMI) 
2.4.1. Harvesting of peripheral blood mononuclear cells 
PBMCs were isolated from whole blood as previously described (Waters et al., 1999). 
PBMCs were resuspended in 1 ml RPMI 1640 media supplemented with 10% FBS, 2 mM L-
glutamine, and 50 ng/ml gentamicin (complete media). 
2.4.2. CFSE proliferation assay 
The lymphocyte proliferation assay coupled with the expression of cell surface 
markers was performed using 5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester 
(CFSE, Molecular Probes, Eugene, OR). Briefly, lxlO7 PBMCs were resuspended in 1 ml of 
sterile PBS. An equal volume of 2.5 pM CFSE was added and incubated at room temperature 
for 5 minutes with periodic mixing followed by the addition of 0.5 ml of FBS to stop the 
reaction. Then, PBMCs were washed once with sterile PBS followed by another wash with 
complete media. PBMCs were adjusted to 5xl06 cells in 1 ml of complete media. One 
hundred p.1 of cells were added to 96-well round-bottomed microliter plates containing media 
alone (negative stimulation), phyto-hemagglutinin (5 jJ,g/ml, positive stimulation), UV-
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inactivated PRRSV VR-2402 or UV-inactivated PRRSV VR-2332 at a multiplicity of 
infection (MOI) of 1 and incubated at 37 C in a 5% CO2, humidified atmosphere for 5 days. 
After a 5-day incubation, the labeled cells were stained with primary monoclonal 
antibodies to swine leukocyte surface antigens including PE-conjugated antiporcine CD4 
(clone 74-12-4) and biotinylated antiporcine CDS (clone 76-2-11) as previously described 
(Waters et al., 1999). The secondary antibody used for detection was conjugated with 
streptavidin (CyChrome, BD Biosciences, San Diego, CA). Proliferation of lymphocyte 
populations were determined by flow cytometry analysis detecting 10,000 events per sample 
(PAC S can, Becton-Dickinson, Mountain View, CA). The relative proliferative index was 
calculated by dividing the percentage of proliferating cells in antigen stimulated wells by the 
percentage of proliferating cells in the well containing media alone. 
2.5. Clinical evaluation 
All pigs were evaluated for clinical respiratory signs and rectal temperatures daily for 
10 days following challenge. A clinical respiratory disease score was given to each pig as 
previously described (Halbur et al., 1995). Pigs with rectal temperatures > 40 C were 
classified as febrile and the number of febrile days for each pig was calculated. 
2.6. Quantitative real time reverse transcriptase polymerase chain reaction (QRT-PCR) 
Analysis of serum for viral RNA quantification was conducted using the QRT-PCR 
protocol described by Vincent et al. (Vincent et al., 2004). In brief, one-tube RT-PCR was 
performed in duplicate for each test serum sample using the Brilliant® single-step QRT-PCR 
system (Stratagene, La Jolla, CA). The reactions were carried out in a Rotor-Gene 4.6 real 
time thermal cycler system (Corbett Research, Mortlake, NSW, Australia). The calculated 
concentrations for the two replicates were averaged to give the copy number per [i\ of the 
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ORF 7 transcript in the sample when the difference between the two samples was less than 
one log unit. If the difference exceeded this limit, the results were considered questionable 
and the sample was re-tested. 
2.7. Statistical analysis 
The data from repeated measurements of antibody response was analyzed by using 
multivariate analysis of variance (ANOVA). Continuous variables including, relative 
lymphocyte proliferation indices the quantity of viral RNA in serum and macroscopic lung 
score were analyzed by ANOVA to determine if there were significant differences among 
treatment groups for each day separately. If the />value for the ANOVA table < 0.05, the 
differences between treatment groups were evaluated by pairwise comparisons using least 
significant difference at thep< 0.05 rejection level. The analysis was also performed within 
and between the challenge virus groups. 
3. RESULTS 
3.1. Antibody responses 
3.1.1. ELISA 
Negative control pigs remained seronegative for PRRSV antibodies as determined by 
IDEXX ELISA throughout the study. Following vaccination, only pigs vaccinated with 
MLV, either alone or followed by KV, were seropositive by ELISA on 28 DPV (Table 2). 
While pigs vaccinated with KV alone remained seronegative until 10 days post challenge, 
pigs vaccinated with KV followed by MLV seroconverted on 42 DPV. Following challenge, 
the KV vaccinated pigs, either alone or followed by MLV, and challenge controls 
seroconverted. The S/P ratios of MLV-vaccinated pigs, either alone or followed by KV, 
remained similar to the ratios prior to challenge. 
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Table 2. 
Antibody response as measured by ELISA of pigs vaccinated with modified live and killed 
PRRSV vaccines, either alone or in combination. All pigs were challenged with either low 
(NADC-8) or high (VR-2385) virulent PRRSV isolates at 44 days post vaccination (0 day 
post infection, DPI). Results were displayed as means of S/P ratio. 
Days post vaccination 
Treatments 0 28 42 
Pre-challenge 
54 
(10 DPI) 
Negative 0.02 (0/5)* 0.03 " (0/5) 0.05b (0/5) 0.06 "(0/5) 
control 
Challenge 0.01 (0/10) 0.03*) (0/10) 0.02 ^  (0/10) 1.41e (10/10) 
control 
KV 0.01 (0/10) 0.02b (0/10) 0
 
0
 cr O
 
O
 
2.45" (10/10) 
MLV 0.01 (0/10) 1.93"(10/10) 1.92" (10/10) 1.89b c (10/10) 
MLV>KV 0.01 (0/10) 2.1 la (10/10) 1.96" (10/10) 1.82b'c (10/10) 
KV>MLV 0.01 (0/10) 0.04 b (0/10) 1.58" (10/10) 2.03a'b (10/10) 
* Number positive/ number tested 
a,b,c Means with different superscripts within a column are statistically different (/?<().05) 
3.1.2 SN antibody response 
Only pigs vaccinated with MLV, either alone or followed by KV, were positive for 
SN antibodies on 28 DPV (Table 3). While SN antibodies against VR-2332 were detected in 
both groups, SN antibodies against VR-2402 were detected in the MLV followed by KV 
group only. Only one pig in MLV alone groups had SN antibodies against VR-2402 on 42 
DPV and the titer was low (1:2). The level of SN antibodies against VR-2402 induced by 
MLV followed by KV was significantly higher than that of MLV alone or KV followed by 
MLV on 28 through 54 DPV, whereas the levels of SN antibodies against VR-2332 in both 
groups were similar. KV-vaccinated pigs remained negative for SN antibodies until 
challenge, but were positive at necropsy. Pigs vaccinated with KV followed by MLV were 
first positive for SN antibodies against both isolates at 42 DPV. Following challenge, levels 
of SN antibodies against both isolates drastically increased in all vaccinated groups, 
especially MLV followed by KV. 
3.2. Proliferative responses of T and B cells to inactivated viruses 
No proliferation of CD4+, CD8+, and CD4+CD8+ T cells were observed in the 
control group. At 42 DPV all T cells regardless of the recall antigens used proliferated 
slightly in all vaccinated groups compared to the non-vaccinated groups (Table 4). At 54 
DPV (10 days following challenge), proliferation of CD4+CD8+ DP T cells was slightly 
increased in groups receiving either KV or MLV alone, however, proliferations of CD4+ and 
CD4+CD8+ DP T cells were significantly increased in the combination vaccination groups. 
The proliferation of CD4+CD8+ DP T cells was observed in groups receiving both MLV and 
KV independent of the order of vaccination, with an increased proliferation index being 
highest when the virus antigen used in the assay corresponded to the first administered 
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Table 3. 
Serum neutralizing antibody response of pigs vaccinated with MLV and KV, either alone or 
in combination. All pigs were challenged with either low (NADC-8) or high (VR-2385) 
virulent PRRSV isolates at 44 days post vaccination. Results were displayed as geometric 
mean titer of SN antibodies. 
SN against VR-2332 SN against VR-2402 
Treatments 28 DPV* 42 DPV 54 DPV 28 DPV 42 DPV 54 DPV 
(10 DPI) (10 DPI) 
Neg 0.00c 0.00 c 0.00 d 0.00 b 0.00 c 0.00 d 
control (0/5) (0/5) (0/5) (0/5) (0/5) (0/5) 
Challenge 0.00' 0.00' 0.00 " 0.00 b 0.00' 0.00 d 
control (0/10) (0/10) (0/10) (0/10) (0/10) (0/10) 
KV 0.00 c 0.00' 0.00 d 0.00 b 0.00' 1.74 c 
(0/10) (0/10) (0/10) (0/10) (0/10) 
MLV 1.51 b 2.00" 4.60 b 0.00 b 1.31 b 3.48 b 
(5/10) (9/10) (9/10) (0/10) (4/10) (9/10) 
MLV>KV 2.14 a 2.14 a 12.13a 2.00" 2.46" 13.00" 
(7/10) (10/10) (10/10) (8/10) (8/10) (10/10) 
KV>MLV 0.00' 1.51 b 2.46' 0.00 b 1.51 b 2.46 b' 
(0/10) (6/10) (10/10) (0/10) (6/10) (10/10) 
* Days post vaccination 
** Number positive/ number tested 
a
'
b c
' Means with different superscripts within a column are statistically different (p<0.05) 
Table 4. 
Relative proliferative indices (PI) of CD4+, CD8+, and CD4+CD8+ DP T lymphocytes in peripheral blood mononuclear cells at 
42 and 54 days post vaccination. 
Treatment 42 days post vaccination 54 days post vaccination (10 days post challenge) 
groups Ex vivo stimulation against 
VR-2332 
Ex vivo stimulation against 
VR-2402 
Ex vivo stimulation against 
VR-2332 
Ex vivo stimulation 
against VR-2402 
CDS CD4 DP CD8 CD4 DP CDS CD4 DP CD8 CD4 DP 
Negative NA* NA NA NA NA NA 0.55 0.60 0.43c 0.55 0.63= 0.72" 
Challenge 0.81 1.02 0.91 0.50 1.11 1.13 1.39 0.67 0.90" 0.83 0.40" 0.54d 
KV 0.85 1.33 0.94 1.05 1.37 1.44 1.08 1.38 1.16b 1.02 1.23"'b 0.89" 
MLV 1.20 1.20 1.06 1.42 1.66 1.21 1.11 1.02 1.28" 1.18 0.59' 1.16b'c 
MLV>KV 1.23 1.26 1.00 1.40 1.60 1.32 1.14 1.72 3.01' 1.54 1.23"'b 2.41" 
KV>MLV 1.11 1.23 1.15 1.12 1.52 1.10 1.23 2.07 1.54b 1.44 2.09" 2.32"'b 
* Not tested 
a
'
b
'
c Means with different superscripts within a column are statistically different (/?<().05) 
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Proliferation of B cells did not differ significantly between vaccination groups (Table 
5). However, at 54 DPV, increased proliferation of B cells was observed in pigs vaccinated 
with KV, either alone or in combination with MLV, regardless of the sequence of 
vaccination. B cells recovered from the MLV>KV group proliferated to VR-2332 stimulation 
more than to VR-2402 stimulation. In contrast, B cells recovered from KV>MLV group 
proliferated to VR-2402 stimulation more than to VR-2332 stimulation. 
3.3. Clinical evaluation 
All groups inoculated with PRRSV showed no symptoms of respiratory disease (data 
not shown). At necropsy, the challenge control groups had the most severe macroscopic lung 
lesions compared to other treatment groups. It appeared that pigs challenged with VR-2385 
had significantly more severe macroscopic lung lesions than pigs challenged with NADC-8 
ip=0.0022). Independent of challenge isolate, pigs vaccinated with MLV, either alone or 
followed by KV, had significantly fewer lung lesions associated with PRRSV compared to 
the challenge control groups and the groups vaccinated with KV, either alone or followed by 
MLV (p<0.001) (Table 6). 
3.4. QRT-PCR 
Only pigs vaccinated with MLV had the detectable level of serum viral RNA prior to 
challenge (Table 7). Following challenge with NADC-8, only one pig in the MLV group had 
the detectable level of serum viral RNA. No pigs in any of the other treatment groups were 
PCR positive. Following challenge with isolate VR-2385, all treatment groups except the 
MLV>KV group, were PCR positive, where the levels of viral RNA detected in both the 
positive control and KV alone vaccination groups were significantly higher than that of other 
Table 5. 
Relative proliferative indices of B lymphocytes in peripheral blood mononuclear cells at 42 and 54 days post vaccination 
Treatment 42 days post vaccination 54 days post vaccination (10 days post 
groups challenge) 
Ex vivo stimulation Ex vivo stimulation Ex vivo stimulation Ex vivo stimulation 
against VR-2332 against VR-2402 against VR-2332 against VR-2402 
Neg control NA* NA 1.01 0.63 
challenge control 0.82 0.72 1.20 1.08 
KV 1.02 1.05 2.47 1.23 
MLV 1.32 1.15 1.40 1.22 
MLV>KV 1.37" 1.34 3.35" 1.98 
KV>MLV 0.95 0.93" 1.94 2.08" 
* Not tested 
a,b Means with different superscripts within a row are statistically different (p<0.05) 
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Table 6. 
Percentage of pneumonia induced by PRRSV at 10 days following challenge with either 
PRRSV VR-2385 or NADC8. 
Treatments Percentage of PRRSV induced pneumonia 
VR-2385 NADC-8 
Negative control 0.00' 0.00' 
Challenge control 22.40"'" 13.60»'" 
KV 14.80" 8.00" 
MLV 2.20' 3.00' 
MLV>KV 3.00' 1.20' 
KV>MLV 20.60»'" 6.60"' 
a
'
b
'
c Means with different superscripts within a column are statistically different (p<0.05) 
treatment groups (p=0.0013). No measurable viral RNA was detected in pigs vaccinated with 
MLV followed by KV. 
4. DISCUSSION 
The effectiveness of current PRRSV vaccines is controversial due to their poor 
performance in inducing immune responses and the occurrence of clinical outbreaks in herds 
following vaccination. The study reported here was conducted to investigate the HI and CMI 
responses of pigs vaccinated with PRRSV MLV and KV, either alone or in combination. The 
protection induced was also evaluated by challenging pigs with heterologous low or high 
virulence isolates of PRRSV. 
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Table 7. 
Level of viral RNA as measured by real time RT-PCR in serum at 10 days post challenge of 
pigs vaccinated with MLV and KV, either alone or in combination. All pigs were challenged 
with either low (NADC-8) or high (VR-2385) virulent PRRSV isolates at 44 days post 
vaccination. Results were displayed as copies/pL 
Treatments Challenge isolate Pre-challenge 
(copies/p-l) 
10 days post challenge 
(copies/jal) 
Negative control No challenge 0.00 (0/5)* 0.00 "(0/5) 
Challenge control VR-2385 0.00 (0/5) 9459.30» (5/5) 
NADC-8 0.00 (0/5) 0.00b (0/5) 
KV VR-2385 0.00 (0/5) 3387.70 *(5/5) 
NADC-8 0.00 (0/5) 0.00b (0/5) 
MLV VR-2385 11.20 (2/5) 35.80"(1/5) 
NADC-8 86.30 (2/5) 215.10b(1/5) 
MLV>KV VR-2385 0.00 (0/5) 0.00b(0/5) 
NADC-8 0.00 (0/5) 0.00b (0/5) 
KV>MLV VR-2385 0.00 (0/5) 315.40b 
NADC-8 0.00 (0/5) 0.00b (0/5) 
a
'
b
'° Means with different superscripts within a column are statistically different (p<0.05) 
* Number of positive/ number tested 
80 
The results of this study demonstrated that KV vaccination did not induce detectable 
levels of PRRSV specific antibodies as measured by either SN or ELISA assays following 
vaccination through 42 DPV and antibodies measured by ELISA rapidly increased by 10 
days post challenge. Vaccination with MLV alone induced a robust antibody response as 
measured by ELISA in which the S/P ratio was high. In contrast, vaccination with MLV 
alone did not induce a strong SN antibody response. The SN antibodies detected in this group 
increased slightly following challenge, whereas antibodies as measured by ELISA remained 
similar to the level prior to challenge. It has been suggested that SN antibodies represent an 
effective immune response against PRRSV, whereas PRRSV specific antibodies as measured 
by ELISA do not correlate with protection (Nelson et al., 1994; Yoon et al., 1995; Osorio et 
al., 2002). The delayed development of SN antibodies induced by PRRSV MLV and KV in 
this study suggests that vaccination of naïve pigs with MLV or KV alone induces a poor 
antibody response, which is similar to previous reports (Osorio et al., 1998). 
Although vaccination with either vaccine alone resulted in the slow development of 
SN antibodies, the use of the combination vaccination protocol, MLV followed by KV, 
resulted in a rapid increase and a higher level of SN antibodies compared to vaccination with 
either vaccine alone. The increased SN antibody levels suggested that this vaccination 
protocol would be more effective against PRRSV compared to vaccination with either 
vaccine alone. It is interesting to note that while pigs vaccinated with MLV followed by KV 
had SN antibodies against VR-2402 significantly higher than pigs vaccinated with MLV 
alone, SN antibodies against VR-2332 were similar in both vaccination groups. These results 
suggest the boostering effect of KV in pigs previously exposed to PRRSV. 
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A previous study conducted in our laboratory demonstrated that pigs vaccinated with 
KV and then challenged with PRRSV responded immunologically to the challenge virus 
more rapidly than non-vaccinated pigs challenged with PRRSV. SN antibodies were 
observed as soon as 2 weeks following PRRSV challenge, in contrast to the 4-5 weeks 
previously described for infected pigs (Yoon et al., 1995). In this study, we observed a 
similar response in the pigs administered KV followed by MLV. SN antibodies were detected 
14 days following the KV booster of MLV in contrast to 28 - 42 days following the use of 
MLV alone. 
In the study reported here, the CMI response induced by vaccination was 
characterized by a lymphocyte proliferative assays using CFSE, a fluorescent dyes coupled 
with the characterization of T cells by monoclonal antibody labeling and flow cytometry 
analysis. The advantage of this technique is it allows the measurement of proliferative 
responses of each subpopulation of T cells. In this study, the proliferation assay was 
performed twice on 42 DPV and 54 DPV (10 days post challenge) using 2 different PRRSV 
isolates, VR-2332 and VR-2402, which represent antigen from MLV and KV, respectively. 
The results demonstrated that vaccination with MLV and KV, either alone or in combination, 
slightly increased proliferative responses of CD4+, CD8+, CD4+CD8+ DP T cells against 
both virus isolates compared to the non-vaccinated group. However, no significant 
differences were detected among those groups that received vaccines. 
Porcine CD4+CD8+ DP T cells are comprised of MHC class II restricted memory 
CD4+ T cells expressing CD8 upon stimulation capable of producing IFN-y. This 
subpopulation of T cells is associated with memory cells as demonstrated by their response to 
recall antigen and expression of memory T cell markers (Pescovitz et al., 1994; Zuckermann, 
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1999; Saalmuller et al., 2002). The increased proliferation of this subpopulation following 
challenge suggests that the immune response against PRRSV following vaccination might be 
mediated by CD4+CD8+ DP T cells. The combined vaccination with MLV and KV, 
however, induced a more rapid response by this sub-population compared to vaccination with 
either vaccine alone or KV followed by MLV. These findings are also in agreement with the 
earlier report, in which the proliferation of CD8+ and CD4+CD8+ DP T cells significantly 
increased following heterologous immunization (Bassaganya-Riera et al., 2004). Although 
proliferation of CD8+ T cells was not observed in our study, it might be due to the time point 
at which the response was measured. Pigs in our study were necropised at 10 DPI, which 
may have been too soon to observe the increased proliferation of CD8+ T cells. The study by 
Bassaganya-Riera et al. (2004), however, demonstrated the increase of CD8+ T cell 
proliferation by 38 DPV. 
In the study reported here, the efficacy of each vaccination protocol was evaluated by 
challenging pigs with two different isolates of PRRSV, a low or a high virulent isolate. These 
two isolates have well been characterized, especially VR-2385, which was demonstrated to 
cause the severe pneumonia at 10 DPI (Halbur et al., 1996). The efficacy of the vaccines was 
evaluated based on the reduction of clinical respiratory disease following challenge, quantity 
of viral RNA in serum, and macroscopic lung lesion at necropsy. Pigs did not display any 
clinical respiratory disease in any of the treatment or control group and no pigs were febrile 
during the 10 DPI. These results were unexpected. However, the results could be due to the 
fact that the pigs were 9 weeks of age at challenge and older pigs are less likely to exhibit 
clinical disease than younger pigs (Rossow et al., 1994; van der Linden et al., 2003). 
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Viral RNA in serum at 10 DPI demonstrated that the administration of the MLV 
followed by KV resulted in a significant reduction of viral RNA compared to the challenge 
control group. Viral RNA was not detected in any of the pigs vaccinated with MLV followed 
by KV, whereas it was still detected in all other vaccinated groups. The efficacy of the 
vaccination protocol based on the reduction of viral RNA in serum at 10 DPI can be 
compared only for pigs challenged with VR-2385. No viral RNA was detected in pigs in the 
NADC-8 challenge control group at any time point. This again could be due to the age of the 
pigs when challenged and the nature of this low virulent PRRSV isolate. Primer and probes 
used in the real time RT-PCR assay were able to detect both isolates. 
It is interesting to note that viral RNA was detected in the pigs vaccinated with MLV 
alone prior to challenge. In contrast, no viral RNA was detected in any pigs in the MLV 
followed by KV group. Whether or not KV vaccination has an effect on viremia remains to 
be further investigated. 
In conclusion, the results of this study demonstrated that vaccination with MLV or 
KV alone induced low HI and CMI responses. However, the administration of KV to 
previously MLV-vaccinated pigs significantly enhanced both HI and CMI responses. 
Furthermore, pigs immunized with this vaccination protocol had reduced viremia following 
challenge. 
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CHAPTER 4. DURATION AND PROTECTION OF MATERNALLY DERIVED 
ANTIBODIES PIGS FARROWED FROM PRRSV-EXPOSED SOWS FOLLOWING 
KILLED PRRSV VACCINE ADMINISTRATION 
A paper to be submitted to Viral Immunology 
D. Nilubol3, B.J. Thackerb, D.L. Harris" and E.L. Thacker3 
^Department of Veterinary Microbiology and Preventive Medicine and 
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ABSTRACT 
Administration of a killed porcine reproductive and respiratory syndrome virus 
(PRRSV) vaccine (KV) to sows pre-farrowing was investigated to determine if an enhanced 
immune response occurred resulting in increased magnitude and duration of maternally 
derived antibody (MDA) and protective immunity for piglets against PRRSV infection. Sows 
from a PRRSV positive herd with no history of KV use were vaccinated at 60 and 75 days of 
gestation. Serological responses were measured in the sows and their offspring. Piglets were 
challenged with PRRSV at 10, 16 and 24 days of age to measure protection. Following 
vaccination, significant increases in ELISA S/P ratios and SN antibodies were observed in 
vaccinated sows at farrowing and weaning, and in their offspring at all times measured. 
Vaccinated sows had significantly higher SN antibodies in colostrum than non-vaccinated 
sows. Pigs farrowed from vaccinated sows and challenged at 10 days of age displayed the 
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mildest clinical disease and had lower levels of serum viral RNA than pigs from non-
vaccinated sows. However, no significant difference in clinical symptoms or PRRSV 
associated pneumonia was detected between pigs farrowed from vaccinated or non-
vaccinated sows at any time point measured. 
The results of this study suggest that the administration of KV in PRRSV-exposed 
sows pre-farrowing significantly increases SN antibodies in serum and colostrum resulting in 
enhanced MDA and protection in young piglets. Although complete protection was not 
observed, pigs with higher MDA had lower levels of viral RNA in their serum when 
challenged at 10 days of age. 
Keywords: PRRSV, modified-live virus vaccine, killed virus vaccine, maternally derived 
antibody, pre-farrowing 
1. INTRODUCTION 
Porcine reproductive and respiratory syndrome virus (PRRSV) infection is endemic 
in many swine operations and causes significant economic losses to swine producers 
worldwide. Several protocols including temporary herd closure have been used to control 
and/or eliminate PRRSV from herds. Regardless of the PRRSV control strategies 
implemented, maintaining a stable sow herd, where virus shedding from sows has ceased, 
appears to be crucial for the successful control of PRRSV. In a stable sow herd, PRRSV 
control appears to be based on maintaining sufficient herd immunity to avoid clinical disease 
and to enable the sow herd to produce PRRSV-negative weaned pigs. 
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It has been shown that PRRSV-positive herds can produce PRRSV-negative weaned 
pigs. However, as demonstrated by several authors (Donadeu et al., 1999; Gramer et al., 
1999; Torremorell et al., 2002), PRRSV-negative pigs are not consistently produced from 
PRRSV-positive herds. Moreover, field observations consistently suggest that pigs often 
seroconvert in the early finishing period (Donadeu et al., 1999; Torremorell et al., 2002). The 
source of infection in this scenario is often unclear. Positive finishing pigs could be laterally 
infected from other pigs including shedding sows in the farrowing house or the pigs could be 
infected vertically in utero. Little information is available regarding the interaction of 
maternal antibody status and infection status of piglets from PRRSV-positive sow herds. One 
explanation for the production of PRRSV-negative piglets from PRRSV-positive sow herds 
could be that the presence of maternal immunity provides the piglets protection from 
infection in addition to protection against clinical disease. The ability of colostral antibodies 
to provide protection against PRRSV infection is not well documented. There are several 
reports discussing the duration of maternally derived antibodies (MDA) resulting from either 
natural infection or vaccination and the information is limited (Albina et al., 1994; Houben et 
al., 1995; Senn et al., 1998). 
Immune responses of pigs are typically enhanced by vaccination. Unfortunately, there 
is considerable controversy over PRRSV vaccine efficacy. Killed PRRSV vaccine (KV) 
induces poor antibody responses in pigs that have not been exposed to the virus. However, 
enhanced SN antibody levels was observed when KV was administered to pigs previously 
infected and/or vaccinated with modified live PRRSV vaccines (MLV) (Nilubol et al., 2004). 
In addition, the use of KV in repeatedly MLV-vaccinated pigs enhanced cellular immune and 
SN antibody responses (Bassaganya-Riera et al., 2004). 
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The objectives of this study were to investigate whether the use of killed PRRSV 
vaccine in sows from a PRRSV positive herd can boost immunity during gestation resulting 
in increased duration and magnitude of MDA in their offspring. This vaccine strategy could 
potentially be used to enhance protection against PRRSV infection in piglets. 
2. MATERIAL AND METHODS 
2.1. Experimental design 
Forty multiparous, PRRSV-exposed sows were randomly selected from a herd 
positive for PRRSV with no history of commercial PRRSV KV use. This farm had 
experienced several PRRSV outbreaks and had used a commercial MLV in the past. The 
PRRSV status of the herd was considered stable at the time of this study due to herd closure. 
Twenty randomly selected sows were vaccinated intramuscularly with a commercial KV 
(PRRomiSe®, Intervet, Millsboro, DE, USA) according to the manufacturer's directions at 
60 and 75 days of gestation. The remaining sows served as non-vaccinated controls. Serum 
was collected from all 40 sows prior to vaccination, 3 days after farrowing and at weaning 
and PRRSV antibodies were measured by ELISA and SN assays. 
Of the 40 sows, 6 vaccinated and 6 non-vaccinated sows (12 total) were selected by 
stratification of parity, serum neutralizing (SN) and ELISA antibody titers prior to KV 
vaccination. Colostrum of those 12 sows was collected within 6 hours after farrowing and 
assayed for SN antibodies. Colostrum was collected, processed and assayed as previously 
described (Wagstrom et al., 2001). 
At 7 days of age, 84 piglets were randomly selected from the 12 sows (7 piglets per 
litter) and transported to an isolation facility at Iowa State University. Each litter was housed 
as a group and serologically monitored over time for antibody responses by ELISA and SN 
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assays. In each litter, four piglets were monitored for the decay of MDA (non-challenge) and 
the remaining 3 piglets were used to measure protection against experimental challenge. 
Serum was collected from piglets in the MDA study at 3, 10, 16, 24, and 33 days of age. The 
rate of antibody decay, measured in half-lives, was determined for all piglets throughout the 
study period. 
In the protection study, 12 randomly selected piglets (1 pig from each litter) were 
taken at 10 (Set 1), 16 (Set 2) and 24 (Set 3) days of age, housed in a separate room, and 
challenged intranasally with 2 ml of 104 TrD50/ml of PRRSV VR-2385 (1 ml/nostril). Serum 
was collected from the piglets prior to challenge, and at 3 and 10 days post challenge, and 
assayed for viral RNA by quantitative realtime RT-PCR (Vincent et al., 2004) and antibodies 
by IDEXX ELISA and SN assays (Nilubol et al., 2004). Clinical signs including rectal 
temperature and respiratory scores (Halbur et al., 1995) were observed daily for 10 days 
following challenge. The percentage of lung tissue exhibiting PRRS V-associated pneumonia 
was recorded at necropsy. 
All study procedures and animal care activities were conducted in accordance with 
the guideline and approval of the Iowa State University Institutional Committee on Animal 
Care and Use. 
2.2. Antibody response 
Serum was assayed for PRRSV-specific antibodies using a commercial ELISA 
(HerdCheck®, IDEXX Laboratories, Westbrook, ME) according to the manufacturer's 
instructions. The presence or absence of antibodies was determined by calculating the 
sample-to-positive (S/P) ratio. A sample was considered to be positive for PRRSV antibodies 
if the S/P ratio was > 0.4. The SN assay was conducted using 2 different isolates of PRRSV 
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(VR-2332 and VR-2402) as previously described (Nilubol et al., 2004). The SN antibody 
titers were reported as the highest serum dilution resulting in a 90% reduction in the number 
of fluorescent focus units per well. Geometric mean titers were calculated. 
2.3. Quantitative real time RT-PCR (QRT-PCR) 
Analysis of serum for viral RNA quantification was conducted using a previously 
described QRT-PCR protocol (Vincent et al., 2004). In brief, one-tube RT-PCR was 
performed in duplicate for each test serum sample using the Brilliant® single-step QRT-PCR 
system (Stratagene, La Jolla, CA). The reactions were carried out in a Rotor-Gene 4.6 real 
time thermal cycler system (Corbett Research, Mortlake, NSW, Australia). The calculated 
concentrations for the two replicates were averaged to give the copy number per /xl of the 
ORF 7 transcript in the sample. 
2.4. Decay rate of MDA 
The decay rate of MDA, measured as antibody half-life, was determined using a 
linear regression curve fitted to the natural logarithms (In) of the antibody titers as measured 
by ELISA and SN antibody assays, which were determined separately. Only pigs with 
ELISA S/P ratio > 0.4 were included for calculation of half-lives as measured by ELISA. 
Antibody half-life estimates were obtained using the equation: h = -(ln2)/b, where h is the 
estimated half-life of antibody and b is the slope of the regression line (Bryan et al., 1990). 
The half-life of MDA for each pig was determined separately and the mean half-life was 
used as a point source estimate. The mean half-life was used for statistical analysis. 
Approximately 95% confidential intervals (C.I.) on the mean half-lives were obtained. 
2.5. Statistical analysis 
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Repeated measure analysis was applied to determine the significant difference 
between vaccinated and non-vaccinated sows. The /rvalue less than 0.05 indicates significant 
difference between 2 treatments. The association between the use of KV and increased 
antibody titer in sows was determined using Fisher's exact test. A linear mixed model using 
procedure REML was used to determine the significant difference between piglets farrowed 
from vaccinated and non-vaccinated sows. 
3. RESULTS 
3.1. Serological responses of sows and offspring following pre-farrowing vaccination 
Administration of a PRRSV KV in sows from a PRRSV-positive herd at 60 and 75 
days of gestation resulted in significantly increased antibody responses at farrowing and 
weaning. While 13 of 18 KV-vaccinated sows had increased levels of SN antibodies, only 
four non-vaccinated sows had the increased SN antibodies. Vaccinated sows also had 
significantly higher ELISA and SN antibody titers compared to non-vaccinated sows (Figure 
1). The significantly increased SN antibodies were mainly against the VR-2402 strain. No 
increase in SN antibodies against VR-2332 was observed. 
The use of PRRSV KV also resulted in increased SN antibody levels in their 
offspring (Figure 2) and colostrum (Table 1). In contrast to SN antibody levels in serum, the 
significantly increased SN antibody levels in colostrum recognized both VR-2402 and VR-
2332. The levels of SN antibodies in colostrum were more concentrated compared to the 
levels detected in the serum of the sows. A positive correlation (r2 = 0.54, p<0.0014) was 
observed between antibodies in colostrum of sows and the serum of piglets at 3 days of age. 
Pigs farrowed from KV vaccinated sows had significantly higher ELISA S/P ratios 
and SN antibody levels compared to pigs farrowed from non-vaccinated sows at all time 
Farrow Wean 
Figure 1. Antibody response of sows following vaccination with killed PRRSV vaccines prior to farrowing. Antibodies 
were measured by serum neutralizing antibody assay using PRRSV isolate VR-2402 as a viral antigen and ELISA. 
Responses were expressed as means + one standard deviation. 
Figure 2. Antibody response of piglets farrowed from sows vaccinated with killed PRRSV vaccines prior to farrowing. 
Antibodies were measured by serum neutralizing antibody assay using PRRSV isolate VR-2402 as a viral antigen and 
ELISA. Responses were expressed as means + one standard deviation. 
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points measured. Regardless of sow vaccination, all pigs had detectable SN antibodies at 3 
and 10 days of age. While 14 of 17 pigs farrowed from vaccinated sows still had detectable 
SN antibodies at 16 and 24 days of age, only 9 and 7 of 17 pigs farrowed from non-
vaccinated sows had detectable SN antibodies. Similar to the SN responses of sows, the 
significantly increased SN antibody levels of pigs were observed mainly against VR-2402 
strain. However, an increased SN response against VR-2332 was also observed. The 
statistical difference between VR-2332 specific SN antibodies of pigs farrowed from 
vaccinated versus non-vaccinated sows except was detected only when the piglets were 10 
days of age. 
3.2. Decay of MDA 
The half-life decay rates of MDA are demonstrated in Table 1. The half-lives of 
MDA as determined by ELISA and SN assays were somewhat higher in pigs farrowed from 
vaccinated sows than pigs farrowed from non-vaccinated sows. However, no significant 
differences were detected. 
3.3. Protection studies 
In order to measure protection provided by MDA, pigs farrowed from both 
vaccinated and non-vaccinated sows were challenged with PRRSV strain VR-2385 at 
approximately 10 (Set 1), 16 (Set 2) and 24 (Set 3) days of age. In all 3 Sets, pigs from 
vaccinated sows had significantly higher SN antibodies against VR-2402 prior to challenge 
than pigs farrowed from non-vaccinated sows (Tables 2-4). While the SN antibodies against 
VR-2332 were detected in Sets 1 and 2, they were absent in all pigs in Set 3. 
Following challenge, clinical respiratory signs associated with PRRSV of pigs in Set 
1 were mild or absent. Although pigs farrowed from vaccinated sows had less severe clinical 
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disease than those of pigs farrowed from non-vaccinated sows, the difference was not 
statistically significant. Independent of the vaccination status of the sows, pigs in Set 1 
displayed the mildest clinical respiratory disease, had fewer febrile days (rectal temperature > 
40 C), and less PRRSV-associated pneumonia compared to pigs in Sets 2 and 3. In contrast, 
clinical respiratory signs were observed in pigs in Sets 2 and 3 within 2 days following 
challenge. No significant differences in average daily gain, respiratory scores, 
Table 1. 
Serum neutralizing antibody response using VR-2332 and VR-2402 isolates in serum at 
farrowing and colostrum of sows following killed vaccines (KV) vaccination at pre-
farrowing and estimated half-lives in days of pigs farrowed from the sows. SN titers are 
displayed as geometric mean titer. 
Colostral SN antibodies Estimated half-lives of MDA (days) in 
against PRRSV piglets (95% confidential interval) 
Sow VR-2332 VR-2402 SN assay SN assay ELISA assay 
vaccination (VR-2332) (VR-2402) 
No KV 5.27" 10.56" 2.97 5.34 5.55 
(6/6)* (6/6) (2.11-3.83) (2.74-7.68) (3.42-7.68) 
KV 28.44* 90.50" 3.79 6 69 8.09 
(6/6) (6/6) (3.03-4.56) (4.79-8.59) (6.72-9.45) 
a,b Significantly different (p<0.05) 
* Number positive/ number tested 
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Table 2. 
Antibody titers prior to challenge, clinical signs, viral RNA in serum and percentage of 
pneumonia following challenge of piglets farrowed from sows vaccinated with or without 
killed PRRSV vaccine (KV) at 10 days of age (Set 1 pigs). Results were displayed as means. 
Sow SN titers at Viral RNA in serum 
prechallenge (xl05copies/ml) 
Summary of Percentage 
clinical signs of 
at 0-10 days pneumonia 
post challenge at 10 days 
VR- VR- Pre­ 3DPI 7DPI 10DPI Resp. Febrile post 
2402 2332 challenge score Days* challenge 
No 2.51" 2.25" 0.00 0.10 3.20 16.80 1.00 3.33 24.50 
KV (3/6)** (3/6) (0/6) (3/6) (6/6) (6/6) 
KV 11.31" 8.00" 0.00 0.00 0.80 2.30 0.83 2.17 12.17 
(6/6) (6/6) (0/6) (0/6) (4/6) (4/6) 
* Pigs with > 40 C rectal temperature were considered to be febrile. 
** Number positive/ number tested 
a,b Means with different superscripts within a column are statistically different (p<0.05) 
febrile days, or PRRSV-associated pneumonia were observed between pigs from vaccinated 
versus non-vaccinated sows in any of the 3 Sets. Levels of viral RNA in the serum of the pigs 
are summarized in Table 2. In Sets 1 and 2, pigs farrowed from vaccinated sows had lower 
levels of viral RNA than pigs farrowed from non-vaccinated sows following challenge. 
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Table 3. 
Antibody titers prior to challenge, clinical signs, viral RNA in serum and percentage of 
pneumonia following challenge of piglets farrowed from sows vaccinated with or without 
killed PRRSV vaccine (KV) at 16 days of age (Set 2 pigs). Results were displayed as means. 
Sow SN titers at Viral RNA in serum 
prechallenge (x 105copies/ml) 
Summary of Percentage 
clinical signs of 
at 0-10 days pneumonia 
post challenge at 10 days 
VR- VR- Pre­ 3DPI 7DPI 10DPI Resp. Febrile post 
2402 2332 challenge score Days* challenge 
No 1.59 zoo 0.00 4.60 6.00 9.70 4.00 11.67 52.00 
KV (2/6)** (4/6) (0/6) (5/6) (6/6) (6/6) 
KV 2.25 2.51 0.00 0.40 3.70 3.10 4.00 12.33 46.00 
(3/6) (4/6) (0/6) (6/6) (5/6) (6/6) 
* Pigs with > 40 C rectal temperature were considered to be febrile. 
** Number positive/ number tested 
a,b Means with different superscripts within a column are statistically different (p<0.05) 
However, no significant difference was detected. The levels of viral RNA in the serum of 
pigs in Set 3 did not differ between pigs farrowed from vaccinated sows versus pigs farrowed 
from non-vaccinated sows. 
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Table 4. 
Antibody titers prior to challenge, clinical signs, viral RNA in serum and percentage of 
pneumonia following challenge of piglets farrowed from sows vaccinated with or without 
killed PRRSV vaccine (KV) at 24 days of age (Set 3 pigs). Results were displayed as means. 
Sow SN titers at Viral RNA in serum 
prechallenge (x 105copies/ml) 
Summary of Percentage 
clinical signs of 
at 0-10 days pneumonia 
post challenge at 10 days 
VR- VR- Pre­ 3DPI 7DPI 10DPI Resp. Febrile post 
2402 2332 challenge score Days* challenge 
No 1.26 0.00 0.00 0.00 0.6 60.5 4.67 12.33 45.33 
KV (2/6)** (0/6) (0/6) (0/6) (5/6) (6/6) 
KV 156 0.00 0.00 0.00 1.4 87.2 5.67 8.50 29.50 
(6/6) (0/6) (0/6) (0/6) (6/6) (6/6) 
* Pigs with > 40 C rectal temperature were considered to be febrile. 
** Number positive/ number tested 
a,b Means with different superscripts within a column are statistically different (/K0.05) 
4. CONCLUSIONS 
Early field studies demonstrated that MDA against PRRSV are typically undetectable 
by 4-6 weeks of age (Albina et al., 1994; Houben et al., 1995). This is considered a relatively 
short period of time compared to MDA to other swine viral pathogens such as swine 
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influenza viras or porcine parvovirus. If PRRSV specific MDA provides protection against 
clinical disease, it would be beneficial to increase the duration and magnitude of PRRSV 
specific MDA. Several studies reported the enhanced immune responses associated with KV 
vaccination in pigs previously exposed to PRRSV (Nilubol et al., 2004; Bassaganya-Riera et 
al., 2004). The study reported here investigated whether administration of KV to sows prior 
to farrowing could enhance the existing immune responses resulting in increased magnitude 
and duration of MDA. This would result in an increased protective immunity in piglets 
against PRRSV infection. 
This study demonstrated that administration of KV to sows from a PRRSV -positive 
herd prior to farrowing resulted in significantly increased antibody responses as measured by 
ELISA and SN assays at farrowing and weaning compared to non-vaccinated sows. The 
increased levels of antibodies were observed in serum and colostrum of sows and the serum 
of their offspring. The increased SN antibody response in the serum of vaccinated sows was 
predominantly against VR-2402 isolate from which the KV was originally developed. 
Increased SN antibody levels against VR-2332, however, were not observed. In contrast to 
SN antibodies in serum of sows, the increased levels of SN antibodies in colostrum were 
against both isolates of PRRSV, VR-2332 and VR-2402. The increased levels of SN 
antibodies in the colostrum of vaccinated sows were significantly higher than non-vaccinated 
sows. As expected, the levels of SN antibodies in colostrum were more concentrated 
compared to those levels detected in the serum of same sows at the time of farrowing. The 
level of antibodies detected in colostrum is dependent on the antibody concentration in the 
serum, as the serum antibodies are transferred into the colostrum during late pregnancy. 
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Although an increase in antibody levels following the KV vaccination was observed 
in most sows, some sows did not respond serologically to the KV vaccination. Non-
responders in this study were evenly divided into two populations, which consisted of either 
gilts having an ELISA S/P ratio lower than the positive cut-off (0.4) and no detectable SN 
antibodies or as 4-7th parity sows having ELISA S/P ratio ranging from 0.4 to 1.067 and SN 
titers of more than 1:8. There are several potential explanations for the lack of immune 
response in these animals. One possible explanation for the lack of response includes that the 
gilts appeared to be negative for PRRSV. This may have been due to insufficient exposure to 
PRRSV in the acclimatization period prior to introduction into the breeding herd. 
Vaccination of these naïve pigs would result in no detectable antibodies similar to previous 
reports (Nilubol et al., 2004). Sows that did not respond to the KV vaccination had SN titers 
of 1:8, 1:32 and 1:64. High antibody levels might interfere with the KV vaccination. Another 
possible reason for the lack of response could be attributed to repeated vaccination with the 
same vaccine, either MLV or KV, which could lead to a diminished to absent immune 
response and thus no increases in antibody or CMI responses was observed (Bassaganya-
Riera et al., 2004). Although this herd had no history of KV vaccine use, this reason cannot 
be ruled out. 
Pigs farrowed from vaccinated sows had significantly higher ELISA S/P ratios and 
SN antibody levels compared to pigs from non-vaccinated sows at all time points measured. 
It is interesting that 94% of pigs farrowed from vaccinated sows had ELISA S/P ratios of 
more than 0.4 and with the majority of them having S/P ratios above 1. In contrast, only 
29.4% of pigs farrowed from non-vaccinated sows had S/P ratios above 0.4. Similar to the 
results observed in sows, the SN antibodies in piglets farrowed from vaccinated sows were 
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predominantly against VR-2402. Serum neutralizing antibodies against VR-2332 were 
observed when pigs were 10 days of age and the levels were significantly higher in pigs 
farrowed from vaccinated sows compared to those farrowed from non-vaccinated sows. 
While the SN antibodies against VR-2332 were still detected in some pigs at 16 days of age, 
they were not detected in any pigs at 24 days of age. In this study, a strong correlation (r2 = 
0.5061, p=0.0025) between the level of SN antibodies and ELISA S/P ratios in the serum of 
pigs farrowed from PRRSV infected sows with or without KV was demonstrated. A high 
positive correlation (r2 = 0.54,^=0.0014) of antibodies in colostrum and antibodies in serum 
of piglets was also demonstrated in this study, which are similar to earlier reports (Albina et 
al., 1994; Houben et al., 1995). 
Following challenge, it appears that MDA against PRRSV protected piglets against 
clinical signs associated with PRRSV infection. However, the protection was observed only 
in pigs challenged at 10 days of age (Set 1) and protection was incomplete as determined by 
continued presence of viral RNA in serum. No protection was present when pigs were 
challenged at 16 (Set 2) and 24 (Set 3) days of age when the SN antibodies were at low 
levels. Pigs in Set 1 displayed very mild clinical respiratory signs and less PRRSV associated 
pneumonia following challenge compared to pigs challenged at 16 or 24 days of age. The 
severity of disease increased when pigs were challenged at the older ages. No significant 
differences in clinical signs and PRRSV associated pneumonia were detected between pigs 
farrowed from vaccinated versus non-vaccinated sows at any age, although pigs at 10 days of 
age with higher levels of SN antibodies in serum tended to have reduced PRRSV associated 
pneumonia. 
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Viral RNA was detected in the serum of pigs farrowed from vaccinated sows, 
although the level of viral RNA was lower compared to those of pigs farrowed from non-
vaccinated sows. In Set 1, the level of viral RNA in serum was somewhat reduced by the 
presence of MDA in the serum of piglets. The viral load in the serum of pigs from Sets 2 and 
3 were not influenced by sow vaccination status. 
The partial protection observed in this study could be due to SN antibodies in the 
colostrum ingested during the first days following farrowing. These SN antibodies in turn 
may have provided protection against clinical disease, but not infection. Complete protection 
by MDA against PRRSV challenge has been previously reported (Morrison et al., 1996), 
which was not in agreement with the results of our study. The difference observed in the 
study reported here could be due to the use of heterologous virus and the dose of PRRSV 
used for challenge. The study by Morrison et al. (1996) used a homologous virus in both the 
sows and pigs and the challenge dosage was lower than 103 2 TCID50/ml. That study also 
demonstrated that the minimum challenge dose necessary to infect pigs in the presence of 
MDA was 103 2 TCID50/ml of VR-2332. In our study, a higher challenge dose of PRRSV 
(104 TCrD5o/ml) was used to challenge pigs and the strain of PRRSV used was heterologous 
to the isolates to which sows had been previously exposed. 
The lack of protection observed when pigs were challenged at an older age could be 
due to the low levels and/ or absence of SN antibodies. Furthermore, SN antibodies may 
enhance PRRSV infection by antibody-dependent enhancement of infection (Yoon et al., 
1996; Shibata et al., 1998). A study from Shibata et al. (1998) demonstrated prolonged 
duration of viremia and virus isolation from tissues following challenge of pigs with a low 
level of maternal immunity. 
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The results of this study suggest that KV could be used in sows from a clinically 
normal, PRRSV-positive herd prior to farrowing as a vaccination protocol to booster the 
herd's existing immunity. The use of KV could increase the duration and magnitude of 
PRRSV specific MDA and allow production of more consistent and healthier piglets with 
lower virus levels. 
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CHAPTER 5: GENERAL CONCLUSIONS 
CONCLUSIONS 
The main objective of the studies reported in this thesis was to develop more effective 
vaccines or vaccination strategies based on commercially available modified live virus 
(MLV) and killed virus (KV) vaccines to control porcine reproductive and respiratory 
syndrome virus (PRRSV). Three separate studies were conducted to investigate the efficacy 
of various vaccination protocols including the addition of interleukin (IL)-12 to enhance the 
efficacy of KV, vaccination with MLV and KV, either alone or in combination, and KV 
vaccination of sows previously exposed to PRRSV in the attempt to increase the magnitude 
and duration of maternally derived antibodies (MDA) in piglets. The protection induced by 
the vaccines or vaccination protocols was also evaluated by challenging pigs with virulent 
PRRSV. 
In the first study, two vaccination protocols, KV with IL-12 as an adjuvant and MLV 
followed by KV were evaluated. It was demonstrated that the addition of IL-12 did little to 
enhance the efficacy of the KV used in this study. Although the KV with IL-12 added 
significantly reduced clinical respiratory disease consistent with PRRSV following challenge 
with the PRRSV isolate VR-2402; however, no reduction of viral RNA in serum or reduced 
persistence of virus in tonsils or BAL was observed. In contrast, the combined protocol of 
MLV followed by KV, appeared to be a promising strategy for increasing the immune 
response induced by commercial PRRSV vaccines. The level of SN antibodies induced by 
the combined vaccination, MLV followed by KV, was higher than vaccination with either 
vaccine alone 42 days post vaccination (DPV). A significant reduction in viral RNA in serum 
and clinical respiratory disease was observed following challenge with VR-2402, although no 
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reduction in viral persistence was detected. Enhancement of the SN antibody response and 
the significant reduction of clinical disease and viral RNA in serum following challenge 
supports the need for further investigation of the potential of this combination vaccination 
protocol (MLV followed by KV) to enhance the immune response against PRRSV. 
The second study was conducted to characterize the immune response and protection 
induced by MLV and KV, either alone or in combination (MLV followed by KV). In this 
study, administration of KV followed by MLV, was also investigated. This vaccination 
protocol was based on findings from the first study that founded KV-vaccinated pigs 
responded immunologically to challenge more rapidly than naïve pigs. This finding led to the 
hypothesis that although the KV does not induce a significant immune response in naïve 
pigs, when administered after virus exposure, the immune system of the host would 
recognize the antigen resulting in an anamnestic response. The study demonstrated that KV 
vaccination alone did not induce a detectable level of antibody as measured by either SN or 
ELISA assays. Although MLV vaccination, either alone or followed by KV, induced similar 
levels of antibodies as measured by ELISA, the MLV+KV regimen induced significantly 
higher levels of SN antibodies at 42 and 54 (10 DPI) DPV compared to either vaccine alone. 
The administration of MLV in previously KV-vaccinated pigs resulted in the detection of SN 
antibodies as soon as 14 days following the booster with MLV in contrast to 28-42 days 
following the MLV alone. Although the SN antibody levels were lower than MLV alone or 
the MLV followed by KV at all time points measured, these results suggest that pigs 
recognized antigen in KV resulting in anamnestic response following MLV. In addition to a 
humoral immune (HI) response, we found that all T-cell populations in all vaccine groups 
had increased proliferative responses compared to the negative control group. However, at 54 
I l l  
DPV (10DPI), the proliferative response of CD4+CD8+ double positive T cells increased 
significantly in the combined vaccination groups regardless of the order of vaccination 
compared to either vaccine alone. 
To evaluate the protection induced by each vaccination protocol, vaccinated pigs 
were challenged with PRRSV. In the first study, pigs were challenged with PRRSV VR-
2402, which is homologous to the isolate used in the KV. In the second study, low (NADC-
8) and high (VR-2385) virulent PRRSV isolates were used. Regardless of the challenge 
isolate, the administration of MLV followed by KV significantly reduced the viral RNA in 
serum, the percentage of lung lesions associated with PRRSV-induced pneumonia, and 
clinical disease as compared to the challenge control and KV vaccination either alone or 
followed by MLV groups. However, none of these vaccination protocols reduced the 
persistence of virus as the challenge virus was detected in the bronchiolar lavage of all pigs. 
The results of the first two studies demonstrated the potential use of a KV as a booster 
vaccine to enhance the existing immunity of pigs. However, they were conducted in an 
experimental setting. Therefore, the third study was conducted in a PRRSV positive herd, 
where several PRRSV outbreaks had occurred and MLV had been previously used. We used 
this herd to investigate whether the use of KV in sows during gestation could boost existing 
immunity resulting in increased levels of maternally derived antibodies (MDA) in their 
offspring. The ability of the increased levels of MDA in piglets to enhance protection against 
experimental PRRSV infection was also assessed. It was demonstrated that KV vaccination 
of PRRSV-exposed sows pre-farrowing significantly increased SN antibodies in serum and 
colostrum of the sows at farrowing and at weaning compared to non-vaccinated sows. 
Furthermore, pigs farrowed from the vaccinated sows had significantly higher antibody 
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levels as measured by both SN and ELISA assays than pigs farrowed from non-vaccinated 
sows. 
It was demonstrated that MDA against PRRSV provides pigs protection against 
clinical disease associated with PRRSV infection following challenge with a heterologous 
PRRSV isolate VR-2385. Pigs challenged at 10 days of age displayed the mildest clinical 
respiratory disease compared to pigs challenge at 16 and 24 days of age. As expected, 10 
day-old pigs had the highest level of SN antibodies in MDA compared to 16 and 24 day-old 
piglets when many piglets no longer had detectable levels of MDA. These results suggest 
that the presence of MDA provided protection against clinical disease. However, the 
protection observed was considered incomplete as viral RNA was still present in the serum 
and macroscopic lung lesions associated with PRRSV-induced pneumonia were present. No 
differences were observed in the severity of clinical signs or the level of viral RNA level in 
serum between pigs farrowed from vaccinated or non-vaccinated sows. Regardless of the KV 
status of the sows, protection was not observed in pigs challenged at 16 and 24 days of age 
when the SN antibodies were at lower levels compared to 10-day old pigs. The results of this 
study demonstrate the incomplete protection provided by MDA against heterologous PRRSV 
challenge and that protection appears to be associated with the level of SN antibodies in 
piglets. 
It is interesting to note that the increased levels of SN antibodies observed following 
the use of KV in MLV vaccinated pigs was predominantly against the VR-2402 isolate, 
which is the PRRSV isolate contained in the KV. The increase in SN antibody levels against 
VR-2332, the isolate used in the MLV, was relatively low and completely absent in some 
pigs. Similar findings were observed in a previous study in which KV was used in sows 
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previously infected with PRRSV or vaccinated with MLV (Bassaganya-Riera et al., 2004; 
Nilubol et al., 2004). It was demonstrated that the significantly increased levels of SN 
antibodies in vaccinated sows and their offspring was predominantly against the VR-2402 
isolate from which the KV was manufactured. These results suggest a boostering effect by 
the KV. In this study, the SN antibody levels against a reference isolate (VR-2332) were also 
measured and the levels were slightly increased. The SN antibodies against the herd specific 
isolate were not measured as the attempt to isolate the herd specific PRRSV was 
unsuccessful and the identification of the isolate circulating in the herd was unknown. 
No matter which PRRSV control strategies employed on a farm, it has been 
demonstrated that controlling virus shedding in the sows is critical for eradication or 
producing PRRSV-free weaned pigs. However, in areas with a high density of swine herds, 
successful PRRSV eradication is often followed by re-infection, apparently from infected 
herds in the vicinity. Therefore in this scenario or in any PRRSV control strategy, herd 
immunity should be maintained at sufficient levels to avoid clinical disease in the sow herd 
and produce PPRSV-free weaned pigs. The problem with PRRSV positive herds is 
inconsistency of herd immunity. Individual immunity within a herd exists at varying levels, 
so protocols to induce more consistent immunity should be considered in order to increase 
the level of overall herd protective immunity. An increase in the level of herd immunity 
would provide increased resistance against re-infection and recurring outbreaks of clinical 
disease. The present studies provide useful information to the swine industry with regard to 
using commercial PRRSV vaccines more effectively to enhance the existing immunity of a 
herd previously infected with PRRSV. Enhancement of SN antibodies and protection against 
disease following the use of KV in pigs infected with PRRSV, either by natural infection or 
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MLV, suggests that the use of KV as a booster vaccine may increase the level of individual 
immunity as well as inducing a more effective immune response. In addition, the results of 
these studies suggest that a combination vaccination protocol, MLV followed by KV, could 
be useful as a prime/boost regimen to increase the efficacy and usefulness of vaccines in the 
reduction of clinical disease and viremia. Although the combined vaccination protocol was 
slightly better than vaccination with MLV alone, the fact that vaccine virus was detected in 
the serum of MLV only vaccinated pigs suggests active shedding of the vaccine virus. This 
issue should be taken into a consideration prior to the use of MLV vaccination. Vaccine virus 
shedding could potentially interfere with control strategies based on virus exclusion. 
Although the virus was not detected in the serum of pigs receiving both vaccines, lack of 
vaccine virus shedding by pigs is not guaranteed. Vaccine virus was found in the bronchiolar 
lavage and whether or not virus would be shed to other pigs was not determined in our 
studies. 
In summary, the three studies suggest that administration of MLV induces a robust 
antibody response not associated with protection and KV does not induce the production of 
detectable levels of antibodies. However, the use of combination protocols, MLV followed 
by KV, appeared to be a more effective strategy due to enhanced levels of SN antibodies 
compared to vaccination with either vaccine alone. In addition, these studies also suggest that 
the KV can be used in PRRSV-positive herds as a pre-farrowing vaccination to enhance the 
antibody levels of sows previously exposed to PRRSV, either by natural infection or MLV 
vaccination. The increased SN antibody levels in sows resulted in an increase in the 
magnitude and duration of maternal antibodies in their offspring. 
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FUTURE STUDIES 
Although the studies reported here suggest that KV can be used to enhance the 
immune response of previously PRRSV infected pigs and the use of MLV and KV as a 
prime/ boost vaccination regimen induces more potent immune responses compared to 
vaccination with either vaccine alone, there remains several aspects that need to be 
investigated further in order to increase the effectiveness of current vaccination and perhaps 
direct the development and evaluation of future vaccines. 
Recently, the relative unresponsiveness of the immune response following repeated 
vaccination of sows with the same vaccine, either MLV or KV, has been demonstrated 
(Bassaganya-Riera et al., 2004). The results of that study suggested the limitation of repeated 
use of KV in PRRSV-exposed pigs. Future studies are needed to further characterize the 
mechanism of immunological unresponsiveness following repeated homologous vaccination. 
A better understanding of this phenomenon will provide important information to the 
development of improved PRRSV vaccines. 
As mentioned above, the use of KV in PRRSV exposed pigs resulted in increased 
levels of SN antibodies predominately against the PRRSV isolate present in the KV, whereas 
the response to the earlier isolate was only slightly increased. This observation leads to the 
hypothesis that the use of KV that contains several PRRSV isolates would result in the 
induction of SN antibodies against several PRRSV isolates, which in turn could broaden the 
immune response against infection and therefore broaden protection. In addition, 
identification of conserved epitopes that are responsible for induction of SN antibodies 
against several PRRSV isolates needs to be determined. Recently, it was demonstrated that 
the epitope responsible for the induction of SN antibodies is on the ectodomain of 
116 
glycoprotein 5 and this epitope appears to be a conserved epitope (Plagemann, 2004). The 
identification of this epitope may facilitate the development of new generation of PRRSV 
vaccines. In addition, this protein could be used as a subunit vaccine to booster the existing 
immune response in the combined vaccination regimens. 
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